Celgene (CELG) 10-Q28 Oct 142014 Q3 Quarterly reportFinancial data

Company Profile

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
Document and Entity Information	Sep. 30, 2014	Oct. 21, 2014
Document and Entity Information	'	'
Entity Registrant Name	'CELGENE CORP /DE/	'
Entity Central Index Key	'0000816284	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Common Stock, Shares Outstanding	'	798,704,188

CONSOLIDATED_STATEMENTS_OF_INC

CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		9 Months Ended
In Millions, except Per Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue:	'	'	'	'
Net product sales	$1,956.80	$1,644	$5,508.90	$4,637.40
Collaborative agreements and other revenue	2.2	2.2	6.8	12.4
Royalty revenue	23.2	28.2	69.2	88.2
Total revenue	1,982.20	1,674.40	5,584.90	4,738
Expenses:	'	'	'	'
Cost of goods sold (excluding amortization of acquired intangible assets)	97.7	86.2	282.7	247.6
Research and development	675.1	584.5	1,845.70	1,495
Selling, general and administrative	497.6	448.7	1,483.50	1,235.80
Amortization of acquired intangible assets	63.7	65.7	194.7	197.1
Acquisition related charges, net	1.5	33.7	11	79.4
Total costs and expenses	1,335.60	1,218.80	3,817.60	3,254.90
Operating income	646.6	455.6	1,767.30	1,483.10
Other income and (expense):	'	'	'	'
Interest and investment income, net	6.9	5.3	20.6	14.6
Interest (expense)	-53.5	-24	-124.4	-61.5
Other income (expense), net	-22.5	5.1	-46.9	12
Income before income taxes	577.5	442	1,616.60	1,448.20
Income tax provision	69	69.5	230.6	212.7
Net income	$508.50	$372.50	$1,386	$1,235.50
Net income per common share (Note1):	'	'	'	'
Basic (in dollars per share)	$0.64	$0.45	$1.72	$1.49
Diluted (in dollars per share)	$0.61	$0.43	$1.66	$1.43
Weighted average shares (Note 1):	'	'	'	'
Basic (in shares)	799.6	824.5	803.5	829.5
Diluted (in shares)	832.8	857.7	836.4	861

CONSOLIDATED_STATEMENTS_OF_COM

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income	$508.50	$372.50	$1,386	$1,235.50
Foreign currency translation adjustments	-36.6	17.9	-32.5	22
Net unrealized gains (losses) related to cash flow hedges:	'	'	'	'
Unrealized holding gains (losses)	382.8	-89.8	342.5	-3.2
Tax (expense) benefit	'	0.2	12.6	'
Unrealized gains (losses), net of tax expense (benefit) of [$x.x] and ($0.2) for the three months ended September 30, 2014, and 2013, respectively, and [$x.x] and $0 for the nine months ended September 30, 2014, and 2013, respectively.	-382.8	89.6	-355.1	3.2
Reclassification adjustment for (gains) losses included in net income	-0.1	-11.1	4.8	-5.1
Tax expense (benefit)	-0.5	-0.3	-1.2	-6.5
Reclassification adjustment for (gains) losses included in net income, net of tax (expense) benefit of [$x.x] and $0.3 for the three months ended September 30, 2014 and 2013, respectively, and [$x.x] and $6.5 for the nine months ended September 30, 2014 and 2013, respectively.	-0.6	-11.4	3.6	-11.6
Net unrealized gains (losses) on marketable securities available for sale:	'	'	'	'
Unrealized holding gains (losses)	64.6	163.1	196.9	216
Tax (expense) benefit	-22.2	-58.5	-67.3	-78.4
Unrealized gains (losses), net of tax expense (benefit) of [$x.x] and $58.5 for the three months ended September 30, 2014 and 2013, respectively, and [$x.x] and $78.4 for the nine months ended September 30, 2014 and 2013, respectively.	42.4	104.6	129.6	137.6
Reclassification adjustment for (gains) losses included in net income	1.2	3	4.2	6.2
Tax expense (benefit)	-0.4	-0.8	-1.5	-1.8
Reclassification adjustment for (gains) losses included in net income, net of tax	0.8	2.2	2.7	4.4
Total other comprehensive income (loss)	388.8	23.7	458.5	149.2
Comprehensive income	$897.30	$396.20	$1,844.50	$1,384.70

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Current assets:	'	'
Cash and cash equivalents	$3,742.50	$3,234.40
Marketable securities available for sale	3,118.20	2,452.60
Accounts receivable, net of allowances of $36.0 and $40.0 at September 30, 2014 and December 31, 2013, respectively	1,068.10	1,061.40
Inventory	372	340.4
Deferred income taxes	25.9	25.3
Other current assets	509.4	436.4
Total current assets	8,836.10	7,550.50
Property, plant and equipment, net	623.6	593.4
Intangible assets, net	4,131.90	2,839.70
Goodwill	2,191.20	2,041.20
Other assets	620.5	353.4
Total assets	16,403.30	13,378.20
Current liabilities:	'	'
Short-term borrowings	100	544.8
Accounts payable	196.7	156.2
Accrued expenses	904.2	1,001.10
Income taxes payable	14.6	16
Current portion of deferred revenue	33.6	27.7
Other current liabilities	148.4	199.7
Total current liabilities	1,397.50	1,945.50
Deferred revenue, net of current portion	28.2	23.7
Income taxes payable	264.2	235
Deferred income taxes	615.1	804.9
Other non-current liabilities	1,592.60	582.7
Long-term debt, net of discount	6,737.30	4,196.50
Total liabilities	10,634.90	7,788.30
Commitments and Contingencies (Note 15)	'	'
Stockholdersâ€™ Equity:	'	'
Preferred stock, $.01 par value per share, 5.0 million shares authorized; none outstanding at September 30, 2014 and December 31, 2013, respectively	0	0
Common stock, $.01 par value per share, 1,150.0 million shares authorized; issued 918.9 million and 906.5 million shares at September 30, 2014 and December 31, 2013, respectively (Note 1)	9.2	9.1
Common stock in treasury, at cost; 118.7 million and 101.5 million shares at September 30, 2014 and December 31, 2013, respectively (Note 1)	-10,091.70	-7,662.10
Additional paid-in capital (Note 1)	9,439.90	8,676.40
Retained earnings	5,858.50	4,472.50
Accumulated other comprehensive income	552.5	94
Total stockholdersâ€™ equity	5,768.40	5,589.90
Total liabilities and stockholdersâ€™ equity	$16,403.30	$13,378.20

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]	'	'
Accounts receivable, allowances (in dollars)	$36	$40
Preferred stock, par value (in dollars per share)	$0.01	$0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$0.01	$0.01
Common stock, shares authorized	1,150,000,000	1,150,000,000
Common stock, shares issued	918,900,000	906,500,000
Common stock, treasury	118,700,000	101,500,000

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net income	$1,386	$1,235.50
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Depreciation	78.1	71.8
Amortization	203.3	205
Deferred income taxes	-248.6	-161.5
Impairment charges	133.2	18.8
Change in value of contingent consideration	11	79.5
Share-based compensation expense	319.2	227.4
Share-based employee benefit plan expense	29.3	25.2
Reclassification adjustment for cash flow hedges included in net income	4.8	-5.1
Unrealized change in value of derivative instruments	-27.8	10.8
Other, net	0.7	14.4
Change in current assets and liabilities, excluding the effect of acquisitions:	'	'
Accounts receivable	-46	-138.7
Inventory	-33.6	-62.6
Other operating assets	55.7	-49.7
Accounts payable and other operating liabilities	74.3	150.7
Income tax payable	27.7	22
Payment of contingent consideration	-5	0
Deferred revenue	11.4	31.7
Net cash provided by operating activities	1,973.70	1,675.20
Cash flows from investing activities:	'	'
Proceeds from sales of marketable securities available for sale	1,662.20	1,936.20
Purchases of marketable securities available for sale	-2,137	-3,237.30
Payments for acquisition of business	-710	0
Purchases of intellectual property and other assets	-21	-19.4
Capital expenditures	-100.9	-93.1
Purchases of investment securities	-58.4	-27.9
Other investing activities	0	-1.9
Net cash used in investing activities	-1,365.10	-1,443.40
Cash flows from financing activities:	'	'
Payment for treasury shares	-2,433.80	-2,068
Proceeds from short-term borrowing	2,436.90	3,761
Principal repayments on short-term borrowing	-2,881.90	-3,665.90
Proceeds from issuance of long-term debt	2,470.60	1,479.60
Proceeds from sale of common equity put options	5.8	0
Payment of contingent consideration	-15	0
Net proceeds from share-based compensation arrangements	205.1	458
Excess tax benefit from share-based compensation arrangements	146.4	139
Net cash (used in) provided by financing activities	-65.9	103.7
Effect of currency rate changes on cash and cash equivalents	-34.6	-2.9
Net increase in cash and cash equivalents	508.1	332.6
Cash and cash equivalents at beginning of period	3,234.40	2,090.40
Cash and cash equivalents at end of period	3,742.50	2,423
Supplemental schedule of non-cash investing and financing activity:	'	'
Acquisition date fair value of contingent consideration issued in business combinations	1,060	0
Change in net unrealized (gain) loss on marketable securities available for sale	-196.9	-216.2
Investment in NantBioScience, Inc. preferred equity	90	0
Supplemental disclosure of cash flow information:	'	'
Interest paid	126.2	67.4
Income taxes paid	$275	$226.20

Nature_of_Business_and_Basis_o

Nature of Business and Basis of Presentation	9 Months Ended
Nature of Business and Basis of Presentation	Sep. 30, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature of Business and Basis of Presentation	'
	Nature of Business and Basis of Presentation

	Celgene Corporation, together with its subsidiaries (collectively “we,” “our,” “us,” “Celgene” or the “Company”) is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. We are dedicated to innovative research and development designed to bring new therapies to market and are involved in research in several scientific areas designed to deliver proprietary next-generation therapies, targeting areas such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

	Our primary commercial stage products include REVLIMID®, ABRAXANE®, POMALYST®/IMNOVID®, VIDAZA® , azacitidine for injection (generic version of VIDAZA®), THALOMID® (inclusive of Thalidomide CelgeneTM), OTEZLA® and ISTODAX®. OTEZLA® was approved by the U.S. Food and Drug Administration (FDA) in March 2014 for the treatment of adult patients with active psoriatic arthritis and in September 2014 for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. We began recognizing revenue related to OTEZLA® during the second quarter of 2014.

	Additional sources of revenue include royalties from Novartis Pharma AG (Novartis) on their sales of FOCALIN XR® and the entire RITALIN® family of drugs, the sale of products and services through our Celgene Cellular Therapeutics (CCT) subsidiary and other licensing agreements.

	The consolidated financial statements include the accounts of Celgene Corporation and its subsidiaries. Investments in limited partnerships and interests where we have an equity interest of 50% or less and do not otherwise have a controlling financial interest are accounted for by either the equity or cost method. Certain prior year amounts have been reclassified to conform to the current year's presentation.

	In June 2014, our stockholders voted to approve an amendment to our Certificate of Incorporation that increased the number of shares of common stock that we are authorized to issue and effected a two-for-one stock split of outstanding shares (Stock Split). As a result, our total number of authorized shares of common stock increased from 575.0 million to 1.150 billion on June 18, 2014. Stockholders of record received one additional share of common stock for each share of common stock owned. All impacted share numbers and per share amounts presented in the accompanying consolidated financial statements and the accompanying notes to the financial statements have been restated to reflect the impact of the Stock Split. Common stock held in treasury was not adjusted for the Stock Split.

	The preparation of the consolidated financial statements requires management to make estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. We are subject to certain risks and uncertainties related to, among other things, product development, regulatory approval, market acceptance, scope of patent and proprietary rights, competition, outcome of legal and governmental proceedings, European credit risk, technological change and product liability.

	Interim results may not be indicative of the results that may be expected for the full year. In the opinion of management, these unaudited consolidated financial statements include all normal and recurring adjustments considered necessary for a fair presentation of these interim unaudited consolidated financial statements.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
Summary of Significant Accounting Policies	Sep. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Summary of Significant Accounting Policies

	Our significant accounting policies are described in Note 1 of Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2013 (2013 Annual Report on Form 10-K).

	New Accounting Pronouncements: In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2014-09, “Revenue from Contracts with Customers” (ASU 2014-09). ASU 2014-09 supersedes nearly all existing revenue recognition guidance under U.S. GAAP and requires revenue to be recognized when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for us beginning in the first quarter of 2017 using one of two prescribed transition methods. Early adoption is not permitted. We are currently evaluating the effect that the updated standard will have on our consolidated financial statements and related disclosures.

Acquisition

Acquisition	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Acquisition	'
	Acquisition

	Nogra Pharma Limited (Nogra): On April 23, 2014, we entered into a license agreement with Nogra, pursuant to which Nogra granted us an exclusive, royalty-bearing license in its intellectual property relating to GED-0301, an antisense oligonucleotide targeting Smad7, to develop and commercialize products containing GED-0301 for the treatment of Crohn’s disease and other indications. A phase II trial of GED-0301 in patients with active Crohn's disease has been completed and we plan to initiate the phase III program for the use of GED-0301 in Crohn's disease before year-end 2014.
	Under the terms of the agreement, which became effective on May 14, 2014 after receipt of certain governmental clearances and approvals, we made an upfront payment of $710.0 million and may make additional contingent developmental, regulatory and sales milestone payments as well as payments based on percentages of annual sales of licensed products. The maximum aggregate amount payable for development and regulatory milestones is approximately $815.0 million, which covers such milestones relating to Crohn’s disease and other indications. Starting from global annual net sales of $500.0 million, aggregate tiered sales milestone payments could total a maximum of $1.050 billion if global annual net sales reach $4.000 billion.
	The development and application of the intellectual property covered under the license agreement will be managed by joint committees composed of members from each of Nogra and us. We have the tie-breaking vote on the joint steering committee and as such have ultimate decision-making authority for development, regulatory and commercialization decisions. The agreement also includes provisions for access to employees of Nogra, technical assistance, transfer of manufacturing agreements and transfer of Nogra know-how related to GED-0301. Based on the foregoing factors, for accounting purposes, we have concluded that the acquired assets meet the definition of a business and have accounted for the GED-0301 license as in-process research and development (IPR&D) acquired in a business combination. The acquisition method of accounting requires that (a) the assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date and (b) the fair value of IPR&D be classified as an indefinite-lived asset until the successful completion or abandonment of the associated research and development efforts. Pro-forma results of operations for this acquisition have not been presented because this acquisition is not material to our consolidated results of operations.
	The fair value of consideration transferred to acquire the license amounted to:


		Fair Value at the Acquisition Date
	Cash	$	710

	Contingent consideration	1,060.00

	Total fair value of consideration transferred	$	1,770.00


	Our potential contingent consideration payments are classified as liabilities, which were measured at fair value as of the acquisition date, with $5.0 million classified as current liabilities and $1.055 billion classified as non-current liabilities. We estimated the fair value of potential contingent consideration using a probability-weighted income approach, which reflects the probability and timing of future potential payments. This fair value measurement is based on significant inputs that are not observable in the market and thus represents a level three liability within the fair value hierarchy. The resulting probability weighted cash flows were discounted using a discount rate based on a market participant assumption.
	The purchase price allocation resulted in the following amounts being allocated to the assets acquired at the acquisition date based on their respective fair values:


		Fair Value at the Acquisition Date
	In-process research and development product rights	$	1,620.00

	Current deferred tax asset	1.3

	Non-current deferred tax liability	(1.3		)
	Total identifiable net assets	1,620.00

	Goodwill	150

	Total net assets acquired	$	1,770.00


	The fair value of the acquired IPR&D asset was based on the present value of expected net cash flows from the GED-0301 product candidate. Net cash flows were determined by estimating future sales, net of the costs to complete development of GED-0301 into a commercially viable product. Estimated net cash flows were adjusted to reflect the probability of successfully developing a new drug from a product candidate that has completed a phase II trial. Additionally, the projections considered the relevant market sizes and growth factors and the nature and expected timing of a new product introduction. The resulting net cash flows from such potential products include our estimates of cost of sales, operating expenses, and income taxes. The rates utilized to discount the net cash flows to their present value were commensurate with the stage of development of the project and uncertainties in the economic estimates used in the projections described above. The acquired IPR&D asset is accounted for as an indefinite-lived intangible asset until regulatory approval in a major market or discontinuation.

	The excess of purchase price over the fair value amounts assigned to the assets acquired represents the goodwill amount resulting from the acquisition. The goodwill recorded as part of the acquisition is largely attributable to intangible assets that do not qualify for separate recognition. We expect this goodwill to be deductible for tax purposes.

	The license agreement may be terminated (i) at our discretion upon 180 days’ written notice to Nogra, provided that such termination will not become effective before May 14, 2017, and (ii) by either party upon material breach of the other party, subject to cure periods. Upon the expiration of our royalty payment obligations under the license agreement, on a country-by-country and licensed product-by-licensed product basis, the license granted under the license agreement will become fully paid-up, irrevocable, perpetual, and non-terminable with respect to such licensed product in such country.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share (Note 1)



		Three-Month Periods Ended September 30,				Nine-Month Periods Ended September 30,
	(Amounts in millions, except per share)	2014		2013		2014		2013
	Net income	$	508.5	$	372.5	$	1,386.00	$	1,235.50

	Weighted-average shares:
	Basic	799.6		824.5		803.5		829.5

	Effect of dilutive securities:
	Options, restricted stock units and other incentives	33.2		33.2		32.9		31.5

	Diluted	832.8		857.7		836.4		861

	Net income per share:
	Basic	$	0.64	$	0.45	$	1.72	$	1.49

	Diluted	$	0.61	$	0.43	$	1.66	$	1.43


	The total number of potential shares of common stock excluded from the diluted earnings per share computation because their inclusion would have been anti-dilutive was 13.7 million and 8.2 million shares for the three-month periods ended September 30, 2014 and 2013, respectively. The total number of potential shares of common stock excluded was 17.9 million and 10.2 million shares for the nine-month periods ended September 30, 2014 and 2013, respectively.

	Share Repurchase Program: In April 2014, our Board of Directors approved an increase of $4.000 billion to our authorized share repurchase program, bringing the total amount authorized since April 2009 to $13.500 billion of our common stock.

	As part of the management of our share repurchase program, we may, from time to time, sell put options on our common stock with strike prices that we believe represent an attractive price to purchase our shares. If the trading price of our shares exceeds the strike price of the put option at the time the option expires, we will have economically reduced the cost of our share repurchase program by the amount of the premium we received from the sale of the put option. If the trading price of our stock is below the strike price of the put option at the time the option expires, we would purchase the shares covered by the option at the strike price of the put option. During the three-month period ended September 30, 2014, we sold put options on $200.0 million notional amount of shares of our common stock, which expired unexercised in September 2014, and recorded a gain from the premium of $3.6 million, which was recorded on the Consolidated Statements of Income in other income (expense), net. During the nine-month period ended September 30, 2014, we recorded a net gain of $9.9 million from selling put options on our common stock. At September 30, 2014, we had no outstanding put options.

	We have purchased 2.8 million and 16.7 million shares of common stock under the share repurchase program from all sources at a total cost of $251.6 million and $2.388 billion during the three- and nine-month periods ended September 30, 2014, respectively. As of September 30, 2014, we had a remaining share repurchase authorization of $3.680 billion.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive Income (Loss)	9 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Accumulated Other Comprehensive Income (Loss)	'
	Accumulated Other Comprehensive Income (Loss)

	The components of other comprehensive income (loss) consist of changes in pension liability, changes in net unrealized gains (losses) on marketable securities classified as available-for-sale, net unrealized gains (losses) related to cash flow hedges and changes in foreign currency translation adjustments.

	The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows:


		Pension				Net Unrealized			Net Unrealized				Foreign				Total
		Liability				Gains (Losses) From			Gains (Losses)				Currency				Accumulated
						Marketable Securities			From Hedges				Translation				Other
													Adjustment				Comprehensive
																	Income (Loss)
	Balance December 31, 2013	$	(6.9	)		$	137.3		$	(36.0	)		$	(0.4	)		$	94

	Other comprehensive income (loss) before reclassifications	—				129.6			355.1				(32.5		)		452.2

	Amounts reclassified from accumulated other comprehensive income	—				2.7			3.6				—				6.3

	Net current-period other comprehensive income (loss)	—				132.3			358.7				(32.5		)		458.5

	Balance September 30, 2014	$	(6.9	)		$	269.6		$	322.7			$	(32.9	)		$	552.5



	Balance December 31, 2012	$	(10.1	)		$	4.2		$	(16.0	)		$	(27.8	)		$	(49.7	)

	Other comprehensive income (loss) before reclassifications	—				137.6			(3.2		)		22				156.4

	Amounts reclassified from accumulated other comprehensive income	—				4.4			(11.6		)		—				(7.2		)

	Net current-period other comprehensive income (loss)	—				142			(14.8		)		22				149.2

	Balance September 30, 2013	$	(10.1	)		$	146.2		$	(30.8	)		$	(5.8	)		$	99.5




					Gains (Losses) Reclassified Out of Accumulated
					Other Comprehensive Income
	Accumulated Other Comprehensive Income Components		Affected Line Item in the Consolidated Statements of Income		Three-Month Periods Ended September 30,							Nine-Month Periods Ended September 30,
					2014			2013				2014				2013
	Gains (losses) from cash-flow hedges:
	Foreign exchange contracts		Net product sales		$	1.3		$	12			$	(1.7	)		$	7.6

	Treasury rate lock agreements		Interest (expense)		(0.9		)	(0.9		)		(2.6		)		(2.5		)
			Income tax benefit (expense)		—			0.3				—				6.5

	Interest rate swap agreements		Interest (expense)		(0.3		)	—				(0.5		)		—

			Income tax benefit (expense)		0.5			—				1.2				—


	Gains (losses) from available-for-sale marketable securities:
	Realized income (loss) on sales of marketable securities		Interest and investment income, net		(1.2		)	(3.0		)		(4.2		)		(6.2		)
			Income tax benefit (expense)		0.4			0.8				1.5				1.8

	Total reclassification, net of tax				$	(0.2	)	$	9.2			$	(6.3	)		$	7.2

Financial_Instruments_and_Fair

Financial Instruments and Fair Value Measurement	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Financial Instruments and Fair Value Measurement	'
	Financial Instruments and Fair Value Measurement

	The table below presents information about assets and liabilities that are measured at fair value on a recurring basis as of September 30, 2014 and the valuation techniques we utilized to determine such fair value. Fair values determined based on Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Our Level 1 assets consist of marketable equity securities. Fair values determined based on Level 2 inputs utilize observable quoted prices for similar assets and liabilities in active markets and observable quoted prices for identical or similar assets in markets that are not very active. Our Level 2 assets consist primarily of U.S. Treasury securities, U.S. government-sponsored agency securities, U.S. government-sponsored agency mortgage-backed securities (MBS), non-U.S. government, agency and Supranational securities, global corporate debt securities, asset backed securities, foreign currency forward contracts and interest rate swap contracts. Fair values determined based on Level 3 inputs utilize unobservable inputs and include valuations of assets or liabilities for which there is little, if any, market activity. We do not have any Level 3 assets. Our Level 1 liability relates to our publicly traded contingent value rights (CVRs). See Note 18 of Notes to Consolidated Financial Statements included in our 2013 Annual Report on Form 10-K for a description of the CVRs. Our Level 2 liabilities relate to foreign currency forward contracts and interest rate swap contracts. Our Level 3 liabilities consist of contingent consideration related to undeveloped product rights resulting from the acquisition of Gloucester Pharmaceuticals, Inc. (Gloucester), contingent consideration related to the undeveloped product rights and the technology platform acquired from the Avila Therapeutics, Inc. (Avila) acquisition, and contingent consideration related to undeveloped product rights, regulatory and sales milestones as well as tiered royalties on sales of licensed products resulting from the acquisition of Nogra. The maximum remaining potential payments related to the contingent consideration from the acquisitions of Gloucester and Avila are estimated to be $120.0 million and $575.0 million, respectively, and $1.865 billion plus amounts based on sales pursuant to the license agreement with Nogra.


		Balance at				Quoted Price in			Significant			Significant
		30-Sep-14				Active Markets for			Other Observable			Unobservable
						Identical Assets			Inputs			Inputs
						(Level 1)			(Level 2)			(Level 3)
	Assets:
	Available-for-sale securities	$	3,118.20			$	717.6		$	2,400.60		$	—

	Forward currency contracts	369.2				—			369.2			—

	Total assets	$	3,487.40			$	717.6		$	2,769.80		$	—

	Liabilities:

	Contingent value rights	$	(146.7	)		$	(146.7	)	$	—		$	—

	Interest rate swaps	(10.3		)		—			(10.3		)	—

	Other acquisition related contingent consideration	(1,250.9		)		—			—			(1,250.9		)

	Total liabilities	$	(1,407.9	)		$	(146.7	)	$	(10.3	)	$	(1,250.9	)

		Balance at				Quoted Price in			Significant			Significant
		December 31, 2013				Active Markets for			Other Observable			Unobservable
						Identical Assets			Inputs			Inputs
						(Level 1)			(Level 2)			(Level 3)
	Assets:

	Available-for-sale securities	$	2,452.60			$	433.1		$	2,019.50		$	—

	Cash equivalents	20				—			20			—

	Total assets	$	2,472.60			$	433.1		$	2,039.50		$	—

	Liabilities:

	Forward currency contracts	$	(9.2	)		$	—		$	(9.2	)	$	—

	Contingent value rights	(118.1		)		(118.1		)	—			—

	Interest rate swaps	(49.6		)		—			(49.6		)	—

	Other acquisition related contingent consideration	(228.5		)		—			—			(228.5		)

	Total liabilities	$	(405.4	)		$	(118.1	)	$	(58.8	)	$	(228.5	)

	There were no security transfers between Levels 1 and 2 during the nine-month periods ended September 30, 2014 and 2013. The following table represents a roll-forward of the fair value of Level 3 instruments:


		Nine-Month Periods Ended September 30,
		2014				2013
	Liabilities:

	Balance at beginning of period	$	(228.5	)		$	(198.1	)
	Amounts acquired or issued	(1,060.0		)		—

	Net change in fair value	17.6				(8.9		)

	Settlements	20				—

Transfers in and/or out of Level 3	—				—

Balance at end of period	$	(1,250.9	)		$	(207.0	)

Level 3 liabilities outstanding as of September 30, 2014 primarily consisted of contingent consideration related to the acquisitions of Avila and Nogra. The $1.022 billion net increase in the fair value of Level 3 liabilities in 2014 included $1.060 billion from the May 2014 acquisition of Nogra, offset slightly by a $20.0 million milestone payment related to our acquisition of Avila. The $17.6 million net reduction in fair value of our Level 3 liabilities during the nine-month period ended September 30, 2014 included a $58.0 million reduction in the fair value of our contingent consideration payable to the former shareholders of Avila due to an adjustment to the probability weighted forecasted cash flows related to CC-292 compared to prior estimates. Changes to the fair value of contingent consideration are recorded on the Consolidated Statements of Income as acquisition related charges, net. The adjustment to the probability weighted forecasted cash flows related to CC-292 also resulted in a reduction in the value of the IPR&D asset recorded in the purchase of Avila (see Note 10).

Derivative_Instruments_and_Hed

Derivative Instruments and Hedging Activities

9 Months Ended

Sep. 30, 2014

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments and Hedging Activities

Our revenue and earnings, cash flows and fair values of assets and liabilities can be impacted by fluctuations in foreign exchange rates and interest rates. We actively manage the impact of foreign exchange rate and interest rate movements through operational means and through the use of various financial instruments, including derivative instruments such as foreign currency option contracts, foreign currency forward contracts, treasury rate lock agreements and interest rate swap contracts. In instances where these financial instruments are accounted for as cash flow hedges or fair value hedges we may from time to time terminate the hedging relationship. If a hedging relationship is terminated we generally either settle the instrument or enter into an offsetting instrument.

Foreign Currency Risk Management

We maintain a foreign exchange exposure management program to mitigate the impact of volatility in foreign exchange rates on future foreign currency cash flows, translation of foreign earnings and changes in the fair value of assets and liabilities denominated in foreign currencies.

Through our revenue hedging program, we endeavor to reduce the impact of possible unfavorable changes in foreign exchange rates on our future U.S. dollar cash flows that are derived from foreign currency denominated sales. To achieve this objective, we hedge a portion of our forecasted foreign currency denominated sales that are expected to occur in the foreseeable future, typically within the next three years. We manage our anticipated transaction exposure principally with foreign currency forward contracts and occasionally foreign currency put and call options.

Foreign Currency Forward Contracts: We use foreign currency forward contracts to hedge specific forecasted transactions denominated in foreign currencies, manage exchange rate volatility in the translation of foreign earnings, and to reduce exposures to foreign currency fluctuations of certain assets and liabilities denominated in foreign currencies.

We manage a portfolio of foreign currency forward contracts to protect against changes in anticipated foreign currency cash flows resulting from changes in foreign currency exchange rates, primarily associated with non-functional currency denominated revenues and expenses of foreign subsidiaries. The foreign currency forward hedging contracts outstanding at September 30, 2014 and December 31, 2013 had settlement dates within 36 months. The spot rate components of these foreign currency forward contracts are designated as cash flow hedges and, to the extent effective, any unrealized gains or losses are reported in other comprehensive income (loss) (OCI) and reclassified to operations in the same periods during which the underlying hedged transactions affect earnings. If a hedging relationship is terminated with respect to a foreign currency forward contract, accumulated gains or losses associated with the contract remain in OCI until the hedged forecasted transaction occurs and are reclassified to operations in the same periods during which the underlying hedged transactions affect earnings. Any ineffectiveness on these foreign currency forward contracts is reported on the Consolidated Statements of Income in other income (expense), net. The forward point components of these foreign currency forward contracts are not designated as cash flow hedges and all fair value adjustments of forward point amounts are recorded to other income (expense), net. Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows at September 30, 2014 and December 31, 2013:

Notional Amount

Foreign Currency

30-Sep-14

31-Dec-13

Australian Dollar

19.7

—

British Pound

360.8

279.4

Canadian Dollar

79.9

—

Euro

3,437.70

3,318.20

Japanese Yen

567.8

559.1

Total

4,465.90

4,156.70

We consider the impact of our own and the counterparties’ credit risk on the fair value of the contracts as well as the ability of each party to execute its obligations under the contract on an ongoing basis. As of September 30, 2014, credit risk did not materially change the fair value of our foreign currency forward contracts.

We also manage a portfolio of foreign currency contracts to reduce exposures to foreign currency fluctuations of certain recognized assets and liabilities denominated in foreign currencies and, from time to time, we enter into foreign currency contracts to manage exposure related to translation of foreign earnings. These foreign currency forward contracts have not been designated as hedges and, accordingly, any changes in their fair value are recognized on the Consolidated Statements of Income in other income (expense), net in the current period. The aggregate notional amount of the foreign currency forward non-designated hedging contracts outstanding at September 30, 2014 and December 31, 2013 were $897.2 million and $878.5 million, respectively.

Interest Rate Risk Management

In anticipation of issuing fixed-rate debt, we may use forward starting interest rate swaps (forward starting swaps) or treasury rate lock agreements (treasury rate locks) that are designated as cash flow hedges to hedge against changes in interest rates that could impact expected future issuances of debt. To the extent these hedges of cash flows related to anticipated debt are effective, any realized or unrealized gains or losses on the treasury rate locks or forward starting swaps are reported in OCI and are recognized in income over the life of the anticipated fixed-rate notes.

Forward Starting Interest Rate Swaps: In anticipation of issuing debt in 2014, we entered into an aggregate notional value of $1.500 billion in forward starting swaps that were designated as cash flow hedges. In April 2014 we accelerated our planned debt issuance date, which resulted in hedge ineffectiveness in the forward starting swaps and a $3.6 million charge to other income (expense), net due to differences between the effective date of the swaps and the accelerated debt issuance date. In addition, all forward starting swaps were settled upon the issuance of debt in May 2014 when the net fair value of the forward starting swaps in accumulated OCI was a loss position of $25.9 million. The net loss of $25.9 million will be recognized as interest expense over the life of the associated senior notes. There were no forward starting swaps outstanding as of September 30, 2014.

Interest Rate Swap Contracts: From time to time we hedge the fair value of certain debt obligations through the use of interest rate swap contracts. The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in interest rates. Since the specific terms and notional amount of the swap are intended to match those of the debt being hedged, it is assumed to be a highly effective hedge and all changes in fair value of the swap are recorded on the Consolidated Balance Sheets with no net impact recorded in income. Any net interest payments made or received on interest rate swap contracts are recognized as interest expense. If a hedging relationship is terminated for an interest rate swap contract, accumulated gains or losses associated with the contract are measured and recorded as a reduction or increase of current and future interest expense associated with the previously hedged debt obligations.

We have entered into swap contracts that were designated as hedges of certain of our fixed rate notes and also terminated the hedging relationship by settling certain of those swap contracts during 2013 and 2014. The settlement of swap contracts resulted in the receipt of net proceeds of $15.3 million and $21.9 million during the nine-month periods ended September 30, 2014 and 2013, respectively, which are accounted for as a reduction of current and future interest expense associated with these notes. See Note 11 for additional details related to reductions of current and future interest expense.

The following table summarizes the notional amounts of our outstanding swap contracts at September 30, 2014 and December 31, 2013:

Notional Amount

30-Sep-14

31-Dec-13

Interest rate swap contracts entered into as fair value hedges of the following fixed-rate senior notes:

2.450% senior notes due 2015

300

1.900% senior notes due 2017

300

2.300% senior notes due 2018

200

2.250% senior notes due 2019

350

—

3.950% senior notes due 2020

500

3.250% senior notes due 2022

850

4.000% senior notes due 2023

100

150

Total

2,600.00

2,300.00

The following tables summarize the fair value and presentation in the Consolidated Balance Sheets for derivative instruments as of September 30, 2014 and December 31, 2013:

30-Sep-14

Asset Derivatives

Liability Derivatives

Instrument

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments:

Foreign exchange contracts*

Other current assets

168.6

Other current assets

41.1

Other current liabilities

—

Other current liabilities

0.2

Other non-current assets

213.6

Other non-current assets

8.4

Other non-current liabilities

0.1

Other non-current liabilities

0.7

Interest rate swap agreements

Other current assets

15.8

Other current assets

—

Other non-current liabilities

—

Other non-current liabilities

27.5

Derivatives not designated as hedging instruments:

Foreign exchange contracts*

Other current assets

48.9

Other current assets

6.6

Other current liabilities

1.4

Other current liabilities

6.4

Interest rate swap agreements

Other non-current assets

1.4

Other non-current assets

—

Total

449.8

90.9

31-Dec-13

Asset Derivatives

Liability Derivatives

Instrument

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments:

Foreign exchange contracts*

Other current assets

63.6

Other current assets

24.9

Other current liabilities

41.5

Other current liabilities

84.7

Other non-current assets

60.6

Other non-current assets

41.9

Other non-current liabilities

4.3

Other non-current liabilities

25.6

Interest rate swap agreements

Other current assets

17.1

Other current assets

—

Other non-current liabilities

—

Other non-current liabilities

68.3

Derivatives not designated as hedging instruments:

Foreign exchange contracts*

Other current assets

11.3

Other current assets

0.7

Other current liabilities

18.7

Interest rate swap agreements

Other current assets

0.1

Other current assets

—

Other non-current assets

1.5

Other non-current assets

—

Total

206

264.8

* Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20.

The following tables summarize the effect of derivative instruments designated as cash-flow hedging instruments on the Consolidated Statements of Income for the three- and nine-month periods ended September 30, 2014 and 2013:

Three-Month Period Ended September 30, 2014

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Recognized in OCI

Reclassified from

Recognized in

on Derivative (1)

Accumulated OCI

Income on

into Income

Derivative

Instrument

(Effective Portion)

(Ineffective Portion

and Amount Excluded

From Effectiveness

Testing)

Foreign exchange contracts

382.8

Net product sales

1.3

Other income, net

(16.4

)

Treasury rate lock agreements

—

Interest expense

(0.9

)

Interest rate swap agreements

—

Interest expense

(0.3

)

(1) Net gains of $132.0 million are expected to be reclassified from Accumulated OCI into income in the next 12 months.

(2) The amount of net losses recognized in income represents $18.6 million of losses related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $2.2 million in gains related to the ineffective portion of the hedging relationships.

Three-Month Period Ended September 30, 2013

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Recognized in OCI

Reclassified from

Recognized in

on Derivative

Accumulated OCI

Income on

into Income

Derivative

Instrument

(Effective Portion)

(Ineffective Portion

and Amount Excluded

From Effectiveness

Testing)

Foreign exchange contracts

(89.8

)

Net product sales

11.9

Other income, net

5.1

-1

Treasury rate lock agreements

—

Interest expense

(0.9

)

(1) The amount of net gains recognized in income represents $5.3 million of gains related to amounts excluded from the assessment of hedge effectiveness and $0.2 million of losses related to the ineffective portion of the hedging relationships.

Nine-Month Period Ended September 30, 2014

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Recognized in OCI

Reclassified from

Recognized in

on Derivative (1)

Accumulated OCI

Income on

into Income

Derivative

Instrument

(Effective Portion)

(Ineffective Portion

and Amount Excluded

From Effectiveness

Testing)

Foreign exchange contracts

374.9

Net product sales

(1.7

)

Other income, net

(19.2

)

Treasury rate lock agreements

—

Interest expense

(2.6

)

Interest rate swap agreements

(32.4

)

Interest expense

(0.5

)

Other income, net

(3.6

)

-3

(1) Net gains of $132.0 million are expected to be reclassified from Accumulated OCI into income in the next 12 months.

(2) The amount of net losses recognized in income represents $22.1 million of losses related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $2.9 million in gains related to the ineffective portion of the hedging relationships.

(3) The amount of net loss recognized in income relates to the ineffective portion of the hedging relationships.

Nine-Month Period Ended September 30, 2013

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Recognized in OCI

Reclassified from

Recognized in

on Derivative

Accumulated OCI

Income on

into Income

Derivative

Instrument

(Effective Portion)

(Ineffective Portion

and Amount Excluded

From Effectiveness

Testing)

Foreign exchange contracts

(3.2

)

Net product sales

7.6

Other income, net

)

Treasury rate lock agreements

—

Interest expense

(2.5

)

(1) The amount of net gains recognized in income represents $7.3 million of gains related to amounts excluded from the assessment of hedge effectiveness and $1.7 million in gains related to the ineffective portion of the hedging relationships.

The following table summarizes the effect of derivative instruments designated as fair value hedging instruments on the Consolidated Statements of Income for the three- and nine-month periods ended September 30, 2014 and 2013:

Amount of Gain (Loss) Recognized in

Income on Derivative

Location of Gain (Loss) Recognized in Income on Derivative

Three-Month Periods Ended September 30,

Nine-Month Periods Ended September 30,

Instrument

2014

2013

2014

2013

Interest rate swap agreements

Interest expense

10.3

9.8

31.2

21.8

The following table summarizes the effect of derivative instruments not designated as hedging instruments on the Consolidated Statements of Income for the three- and nine-month periods ended September 30, 2014 and 2013:

Amount of Gain (Loss) Recognized in

Income on Derivative

Location of Gain (Loss) Recognized in Income on Derivative

Three-Month Periods Ended September 30,

Nine-Month Periods Ended September 30,

Instrument

2014

2013

2014

2013

Foreign exchange contracts

Other income (expense), net

55.4

(27.0

)

44.3

(42.2

)

Put options on our common stock

Other income (expense), net

3.6

—

9.9

—

The impact of gains and losses on foreign exchange contracts not designated as hedging instruments related to changes in the fair value of assets and liabilities denominated in foreign currencies are generally offset by net foreign exchange gains and losses, which are also included on the Consolidated Statements of Income in other income (expense), net for all periods presented. When we enter into foreign exchange contracts not designated as hedging instruments to mitigate the impact of exchange rate volatility in the translation of foreign earnings, gains and losses will generally be offset by fluctuations in the U.S. Dollar translated amounts of each Income Statement account in current and/or future periods.

Cash_Cash_Equivalents_and_Mark

Cash, Cash Equivalents and Marketable Securities Available-for-Sale	9 Months Ended
	Sep. 30, 2014
Cash, Cash Equivalents, and Short-term Investments [Abstract]	'
Cash, Cash Equivalents and Marketable Securities Available-for-Sale	'
	Cash, Cash Equivalents and Marketable Securities Available-for-Sale

	Money market funds of $2.285 billion and $1.697 billion at September 30, 2014 and December 31, 2013, respectively, were recorded at cost, which approximates fair value and are included in cash and cash equivalents. The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale securities by major security type and class of security at September 30, 2014 and December 31, 2013 were as follows:


	30-Sep-14	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss			Estimated Fair Value
	U.S. Treasury securities	$	1,012.80	$	0.4	$	(0.7	)	$	1,012.50

	U.S. government-sponsored agency securities	195.5		0.2		(0.2		)	195.5

	U.S. government-sponsored agency MBS	556.4		0.7		(3.6		)	553.5

	Non-U.S. government, agency and Supranational securities	19.9		—		(0.1		)	19.8

	Corporate debt - global	438.8		1.1		(0.6		)	439.3

	Asset backed securities	180.2		—		(0.2		)	180

	Marketable equity securities	299.9		418.2		(0.5		)	717.6

	Total available-for-sale marketable securities	$	2,703.50	$	420.6	$	(5.9	)	$	3,118.20




	December 31, 2013	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss			Estimated Fair Value
	U.S. Treasury securities	$	795.2	$	0.3	$	(0.4	)	$	795.1

	U.S. government-sponsored agency securities	208.9		0.2		(0.2		)	208.9

	U.S. government-sponsored agency MBS	450.8		0.1		(6.9		)	444

	Non-U.S. government, agency and Supranational securities	10.4		—		—			10.4

	Corporate debt - global	379.2		1.1		(0.6		)	379.7

	Asset backed securities	181.6		—		(0.2		)	181.4

	Marketable equity securities	212.9		220.2		—			433.1

	Total available-for-sale marketable securities	$	2,239.00	$	221.9	$	(8.3	)	$	2,452.60


	U.S. government-sponsored agency securities include general unsecured obligations either issued directly by or guaranteed by U.S. Government Sponsored Enterprises. U.S. government-sponsored agency MBS include mortgage-backed securities issued by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation and the Government National Mortgage Association. Non-U.S. government, agency and Supranational securities consist of direct obligations of highly rated governments of nations other than the United States and obligations of sponsored agencies and other entities that are guaranteed or supported by highly rated governments of nations other than the United States. Corporate debt-global includes obligations issued by investment-grade corporations, including some issues that have been guaranteed by governments and government agencies. Asset backed securities consist of triple-A rated securities with cash flows collateralized by credit card receivables and auto loans. Marketable equity securities consist of investments in equity securities that have become publicly traded. The increase in net unrealized gains in marketable equity securities during the nine-month period ended September 30, 2014 primarily reflects the increase in market value for certain equity investments subsequent to December 31, 2013.

	Duration periods of available-for-sale debt securities at September 30, 2014 were as follows:



		Amortized		Fair
		Cost		Value
	Duration of one year or less	$	438.1	$	438.6

	Duration of one through three years	1,760.30		1,758.70

	Duration of three through five years	205.2		203.3

	Total	$	2,403.60	$	2,400.60

Inventory

Inventory	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Inventory	'
	Inventory

	A summary of inventories by major category at September 30, 2014 and December 31, 2013 follows:


		30-Sep-14		31-Dec-13
	Raw materials	$	174	$	147.4

	Work in process	114.4		99.6

	Finished goods	83.6		93.4

	Total	$	372	$	340.4

Intangible_Assets_and_Goodwill

Intangible Assets and Goodwill	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Intangible Assets and Goodwill	'
	Intangible Assets and Goodwill

	Intangible Assets: Our finite lived intangible assets primarily consist of developed product rights and technology obtained from the Pharmion Corp. (Pharmion), Gloucester, Abraxis BioScience, Inc. (Abraxis) and Avila acquisitions. Our indefinite lived intangible assets consist of acquired IPR&D product rights from the Nogra and Gloucester acquisitions. The remaining weighted-average amortization period for finite-lived intangible assets not fully amortized is approximately 11.3 years.

	The following summary of intangible assets by category includes intangibles currently being amortized and intangibles not yet subject to amortization:


	30-Sep-14	Gross Carrying Value		Accumulated Amortization			Intangible Assets, Net
	Amortizable intangible assets:

	Acquired developed product rights	$	3,405.90	$	(1,183.1	)	$	2,222.80

	Technology	333.7		(123.2		)	210.5

	Licenses	66.2		(17.0		)	49.2

	Other	42.6		(21.9		)	20.7

		3,848.40		(1,345.2		)	2,503.20

	Non-amortized intangible assets:

	Acquired IPR&D product rights	1,628.70		—			1,628.70

	Total intangible assets	$	5,477.10	$	(1,345.2	)	$	4,131.90


	31-Dec-13	Gross Carrying Value		Accumulated Amortization			Intangible Assets, Net
	Amortizable intangible assets:

	Acquired developed product rights	$	3,405.90	$	(1,026.4	)	$	2,379.50

	Technology	333.7		(87.4		)	246.3

	Licenses	66.2		(13.9		)	52.3

	Other	42.5		(18.8		)	23.7

		3,848.30		(1,146.5		)	2,701.80

	Non-amortized intangible assets:

	Acquired IPR&D product rights	137.9		—			137.9

	Total intangible assets	$	3,986.20	$	(1,146.5	)	$	2,839.70


	The $1.491 billion increase in the gross carrying value of intangible assets during the nine-month period ended September 30, 2014 was primarily due to the addition of $1.620 billion of IPR&D from the Nogra acquisition, partly offset by a $129.2 million impairment charge recorded as research and development expense to write down the IPR&D asset recorded for the CC-292 program due to an adjustment to the probability weighted forecasted cash flows related to CC-292 compared to prior estimates. The adjustment to the probability weighted forecasted cash flows related to CC-292 also resulted in a $58.0 million reduction in the fair value of our contingent consideration payable to the former shareholders of Avila (see Note 6).

	Amortization expense related to intangible assets was $65.0 million and $67.5 million for the three-month periods ended September 30, 2014 and 2013, respectively, and $198.8 million and $201.6 million for the nine-month periods ended September 30, 2014 and 2013, respectively. Assuming no changes in the gross carrying amount of intangible assets, the amortization of intangible assets for years 2014 through 2018 is estimated to be in the range of approximately $255.0 million to $265.0 million annually.

	Goodwill: At September 30, 2014, our goodwill related to the April 2014 Nogra acquisition (see Note 3), the 2012 acquisition of Avila, the 2010 acquisitions of Abraxis and Gloucester, the 2008 acquisition of Pharmion and the 2004 acquisition of Penn T Limited.

	The carrying value of goodwill increased by $150.0 million to $2.191 billion as of September 30, 2014 compared to December 31, 2013 due to the Nogra acquisition.

Debt

Debt	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Debt

	Senior Notes: Summarized below are the carrying values of our senior notes at September 30, 2014 and December 31, 2013:



		30-Sep-14		31-Dec-13
	2.450% senior notes due 2015	$	508.2	$	513.9

	1.900% senior notes due 2017	500.3		499.9

	2.300% senior notes due 2018	400.1		399

	2.250% senior notes due 2019	498.8		—

	3.950% senior notes due 2020	495.4		484.6

	3.250% senior notes due 2022	991.1		956.6

	4.000% senior notes due 2023	704		696.3

	3.625% senior notes due 2024	996.7		—

	5.700% senior notes due 2040	249.6		249.6

	5.250% senior notes due 2043	396.6		396.6

	4.625% senior notes due 2044	996.5		—

	Total long-term debt	$	6,737.30	$	4,196.50


	At September 30, 2014, the fair value of our outstanding Senior Notes was $6.866 billion and represented a Level 2 measurement within the fair value measurement hierarchy.

	In May 2014, we issued an additional $2.500 billion principal amount of senior notes consisting of $500.0 million aggregate principal amount of 2.250% Senior Notes due 2019 (the 2019 notes), $1.000 billion aggregate principal amount of 3.625% Senior Notes due 2024 (the 2024 notes) and $1.000 billion aggregate principal amount of 4.625% Senior Notes due 2044 (the 2044 notes and together with the 2019 notes and 2024 notes, referred to herein as the “2014 issued notes”). The 2014 issued notes were issued at 99.751%, 99.659% and 99.646% of par, respectively, and the discount is being amortized as additional interest expense over the period from issuance through maturity. Offering costs of approximately $21.2 million have been recorded as debt issuance costs on our Consolidated Balance Sheets and are being amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. Interest on the 2014 issued notes is payable semi-annually in arrears on May 15 and November 15 each year beginning November 15, 2014 and the principal on each 2014 issued note is due in full at their respective maturity dates. The 2014 issued notes may be redeemed at our option, in whole or in part, at any time at a redemption price equaling accrued and unpaid interest plus the greater of 100% of the principal amount of the 2014 issued notes to be redeemed or the sum of the present values of the remaining scheduled payments of interest and principal discounted to the date of redemption on a semi-annual basis plus 10 basis points in the case of the 2019 notes, 15 basis points in the case of the 2024 notes and 20 basis points in the case of the 2044 notes. If we experience a change of control accompanied by a downgrade of the debt to below investment grade, we will be required to offer to repurchase the 2014 issued notes at a purchase price equal to 101% of their principal amount plus accrued and unpaid interest. We are subject to covenants which limit our ability to pledge properties as security under borrowing arrangements and limit our ability to perform sale and leaseback transactions involving our property.

	From time to time, we have used treasury rate locks and forward starting interest rate swap contracts to hedge against changes in interest rates in anticipation of issuing fixed-rate notes. As of September 30, 2014, a balance of $53.3 million in losses remained in OCI related to these derivative instruments and will be recognized as interest expense over the life of the notes.

	At September 30, 2014, we were party to pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes as described in Note 7. Our swap contracts outstanding at September 30, 2014 effectively convert the hedged portion of our fixed-rate notes to floating rates. From time to time we terminate the hedging relationship on certain of our swap contracts by settling the contracts or by entering into offsetting contracts. Any net proceeds received or paid in these settlements are accounted for as a reduction or increase of current and future interest expense associated with the previously hedged notes. As of September 30, 2014, we had a balance of $32.7 million of unamortized gains recorded as a component of our debt as a result of past swap contract settlements, including $8.8 million related to the settlement of swap contracts during the nine months ended September 30, 2014. As of December 31, 2013, we had a balance of $32.1 million of unamortized gains recorded as a component of our debt as a result of past swap contract settlements.

	Commercial Paper: The carrying value of Commercial Paper as of September 30, 2014 and December 31, 2013 was $100.0 million and $544.8 million, respectively, and approximated its fair value. The effective interest rate on our outstanding Commercial Paper at September 30, 2014 was 0.3%.

	Senior Unsecured Credit Facility: In September 2011, we entered into a senior unsecured revolving credit facility (Credit Facility) providing for revolving credit. The Credit Facility is currently at an aggregate maximum amount of $1.500 billion with an expiration date of April 18, 2018. Subject to certain conditions, we have the right to increase the amount of the Credit Facility (but in no event more than one time per annum), up to a maximum aggregate amount of $1.750 billion.

	Amounts may be borrowed under the Credit Facility for working capital, capital expenditures and other corporate purposes. The Credit Facility serves as backup liquidity for our Commercial Paper borrowings. As of September 30, 2014 and December 31, 2013 there were no outstanding borrowings under the Credit Facility.

	The Credit Facility contains affirmative and negative covenants, including certain customary financial covenants. We were in compliance with all financial covenants as of September 30, 2014.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Share-Based Compensation	'
	Share-Based Compensation

	We have a stockholder-approved stock incentive plan, the 2008 Stock Incentive Plan (amended and restated as of April 17, 2013 and as further amended on April 17, 2014) (Plan) which provides for the granting of options, restricted stock awards (RSUs), stock appreciation rights, performance awards (PSUs) and other share-based awards to our employees and officers. The Management Compensation and Development Committee of the Board of Directors (Compensation Committee) may determine the type, amount and terms, including vesting, of any awards made under the Plan.

	On June 18, 2014, our stockholders approved an amendment of the Plan, which included the following key modifications: adoption of an aggregate share reserve of 228.0 million shares of Common Stock (after giving effect to the Stock Split), which includes 18.0 million new post-split shares of Common Stock; and an extension of the term of the Plan through April 16, 2024.

	The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Income for the three- and nine-month periods ended September 30, 2014 and 2013:



		Three-Month Periods Ended September 30,							Nine-Month Periods Ended September 30,
		2014			2013				2014		2013
	Cost of goods sold (excluding amortization of acquired intangible assets)	$	6.8		$	6.1			$	18.8	$	12.6

	Research and development	48.4			41.7				141.2		100.5

	Selling, general and administrative	56.2			44.2				159.2		114.3

	Total share-based compensation expense	111.4			92				319.2		227.4

	Tax benefit related to share-based compensation expense	31.4			29.9				92.4		66.1

	Reduction in income	$	80		$	62.1			$	226.8	$	161.3


	We utilize share-based compensation in the form of stock options, RSUs and PSUs. The following table summarizes the activity for stock options, RSUs and PSUs for the nine-month period ended September 30, 2014 (in millions unless otherwise noted):


		Stock		Restricted Stock			Performance-
		Options		Units			Based Restricted
							Stock Units
							(in thousands)
	Outstanding at December 31, 2013	79.2		10.2			115

	Changes during the Year:

	Granted	10.6		1.8			48

	Exercised / Released	(9.6	)	(2.2	)		(24	)
	Forfeited	(1.3	)	(0.3	)		(6	)
	Outstanding at September 30, 2014	78.9		9.5			133


	Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2014 were as follows (dollars in millions):


		Stock			Restricted Stock				Performance-
		Options			Units				Based Restricted
									Stock Units
	Unrecognized compensation cost	$	500.3		$	277.8			$	6.3

	Expected weighted-average period in years of compensation cost to be recognized	2.1			1.3				1.8

Income_Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes

	We regularly evaluate the likelihood of the realization of our deferred tax assets and reduce the carrying amount of those deferred tax assets by a valuation allowance to the extent we believe a portion will not be realized. We consider many factors when assessing the likelihood of future realization of our deferred tax assets, including recent cumulative earnings experience by taxing jurisdiction, expectations of future taxable income, the carryforward periods available to us for tax reporting purposes and other relevant factors. Significant judgment is required in making this assessment.

	Our tax returns are under routine examination in many taxing jurisdictions. The scope of these examinations includes, but is not limited to, the review of our taxable presence in a jurisdiction, our deduction of certain items, our claims for research and development credits, our compliance with transfer pricing rules and regulations and the inclusion or exclusion of amounts from our tax returns as filed. Our U.S. federal income tax returns have been audited by the Internal Revenue Service (IRS) through the year ended December 31, 2008. Tax returns for the years ended December 31, 2009, 2010 and 2011 are currently under examination by the IRS. We are also subject to audits by various state and foreign taxing authorities, including, but not limited to, most U.S. states and major European and Asian countries where we have operations.

	We regularly reevaluate our tax positions and the associated interest and penalties, if applicable, resulting from audits of federal, state and foreign income tax filings, as well as changes in tax law (including regulations, administrative pronouncements, judicial precedents, etc.) that would reduce the technical merits of the position to below more likely than not. We believe that our accruals for tax liabilities are adequate for all open years. Many factors are considered in making these evaluations, including past history, recent interpretations of tax law and the specifics of each matter. Because tax regulations are subject to interpretation and tax litigation is inherently uncertain, these evaluations can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions. We apply a variety of methodologies in making these estimates and assumptions, which include studies performed by independent economists, advice from industry and subject experts, evaluation of public actions taken by the IRS and other taxing authorities, as well as our industry experience. These evaluations are based on estimates and assumptions that have been deemed reasonable by management. However, if management’s estimates are not representative of actual outcomes, our results of operations could be materially impacted.

	Unrecognized tax benefits, generally represented by liabilities on the consolidated balance sheet and all subject to tax examinations, arise when the estimated benefit recorded in the financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues common among multinational corporations. Virtually all of these unrecognized tax benefits, if recognized, would impact the effective income tax rate. We account for interest and potential penalties related to uncertain tax positions as part of our provision for income taxes. For the nine-month period ended September 30, 2014 gross unrecognized tax benefits increased by $29.2 million, primarily from unrecognized tax benefits related to current year operations of $31.9 million and accrued interest of $5.0 million, partially offset by a net decrease in unrecognized tax benefits related to ongoing examinations and settlements of tax positions taken in prior years of $7.7 million. The liability for unrecognized tax benefits is expected to increase in the next 12 months relating to operations occurring in that period. Any settlements of examinations with taxing authorities or statute of limitations expirations would likely result in a decrease in our liability for unrecognized tax benefits and a corresponding increase in taxes paid or payable and/or a decrease in income tax expense. Our estimates of tax benefits and potential tax benefits may not be representative of actual outcomes and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire.

Collaboration_Agreements

Collaboration Agreements	9 Months Ended
Collaboration Agreements	Sep. 30, 2014
Collaboration Agreements [Abstract]	'
Collaboration Agreements	'
	Collaboration Agreements

	From time to time, we enter into collaborative arrangements for the research and development, license, manufacture and/or commercialization of products and/or product candidates. In addition, we also acquire product and research and development technology rights and establish research and development collaborations with third parties to enhance our strategic position within our industry by strengthening and diversifying our research and development capabilities, product pipeline and marketed product base. These arrangements may include non-refundable, upfront payments, option payments for the purchase or license of additional rights, development, regulatory and commercial performance milestone payments, cost sharing arrangements, royalty payments and profit sharing. Certain of these arrangements obligate us to make additional equity investments in the event of an initial public offering of equity by our partners. The activities under these collaboration agreements are performed with no guarantee of either technological or commercial success. We do not consider any of the following arrangements to be material. See Note 17 of Notes to Consolidated Financial Statements included in our 2013 Annual Report on Form 10-K for a description of certain other collaboration agreements entered into prior to January 1, 2014. The following is a brief description of significant developments in the relationships between Celgene and our collaboration partners during the nine months ended September 30, 2014:

	Sutro Biopharma, Inc. (Sutro): In December 2012, we entered into a collaboration and license agreement with Sutro for the development of an antibody drug conjugate (ADC) and a bispecific antibody construct (BAC). Sutro controls and conducts initial development activities. We have the right to select one ADC among a number of different sequence-payload combinations and positional variants, and one BAC. Sutro will provide adequate quantities of any selected ADC and selected BAC to allow us to conduct all necessary preclinical studies, including toxicology and pharmacokinetics studies.

	Under the terms of the 2012 agreement, Sutro received payments totaling $35.0 million, which included an equity investment and other rights. In addition, the 2012 collaboration and license agreement includes certain development and regulatory milestones that could total up to $204.0 million for a selected ADC if approved in multiple indications, and up to $279.0 million for a selected BAC if approved in multiple indications, as well as tiered royalties based on annual net sales of licensed products.

	In September 2014, we entered into a second collaboration and license agreement with Sutro to jointly develop up to six prioritized anti-cancer BACs and/or ADCs directed primarily to immune-oncology targets. Sutro will control and conduct initial development activities. We have the right to advance any BAC and/or ADC to investigational new drug (IND)-enabling studies or to designate it as a development candidate, and in either case, we would then have the sole right and responsibility for development activities, although Sutro would still have certain limited manufacturing and supply obligations.

	Under the terms of the 2014 agreement, Sutro received payments totaling $95.0 million, which includes an equity investment that increases our ownership to approximately 15%, rights with respect to manufacturing and supply of BAC and ADC development candidates, and an option to acquire all of the outstanding equity of Sutro based on a pre-specified valuation procedure. The option is exercisable beginning September 2016 and expires upon the termination of the research term (as extended).

	For a future one-time payment, we have the right to obtain access to Sutro’s proprietary protein expression platform to use in conjunction with our intellectual property. Additionally, we have the right to have Sutro evaluate the performance of certain monospecific ADCs directed against up to five non-natural amino acid targets, and reengineer, express, and provide antibodies which incorporate a single non-natural amino acid sequence in a number of preferred locations.

	The research term of the collaboration and license agreement is three years, with an extension available for an additional one-and-a-half years for a payment of an additional fee. We have worldwide commercialization rights for development candidates in which at least one binding domain is directed to a certain undisclosed target, plus the first development candidate which does not include at least one binding domain directed to that certain undisclosed target but which achieves IND clearance in the U.S. For all other development candidates, Sutro has U.S. rights, while we have all ex-U.S. rights.

	Under the terms of the 2014 agreement, Sutro is eligible to receive research and manufacturing milestones of up to $75.0 million, clinical development and regulatory approval milestones of up to $275.0 million for each compound selected under the collaboration if approved in multiple indications, as well as tiered royalties based on annual net sales of licensed products.

	The collaboration and license agreement may be terminated by us for convenience on a program-by-program basis upon one hundred twenty (120) days prior written notice, or by either party for material breach, intellectual property challenge, or bankruptcy by the other party. With certain exceptions, the collaboration and license agreement expires in its entirety upon the expiration of all applicable royalty terms under the Agreement.

	Agios Pharmaceuticals, Inc. (Agios): During 2010, we entered into a discovery and development collaboration and license agreement with Agios that focuses on cancer metabolism targets and the discovery, development and commercialization of associated therapeutics. We have an exclusive option through the end of phase I clinical trials to license any potential products that result from the Agios cancer metabolism research platform.

	With respect to each product that we choose to license, Agios could receive up to approximately $120.0 million upon achievement of certain milestones and other payments plus royalties on sales, and Agios may also participate in the development and commercialization of certain products in the United States. Our option to license a product will terminate on April 14, 2015.

	In June 2014, we exercised our option to license AG-221 from Agios on an exclusive worldwide basis, with Agios retaining the right to conduct a portion of commercialization activities for AG-221 in the United States. AG-221 is currently in a phase I study in patients that harbor an IDH2 mutation with advanced hematologic malignancies, including acute myeloid leukemia (AML).

	FORMA Therapeutics Holdings, LLC (FORMA): On April 19, 2013, we entered into a collaboration agreement with FORMA under which the parties will discover, develop and commercialize drug candidates to regulate protein homeostasis targets. Protein homeostasis, which is important in oncology, neurodegenerative and other disorders, involves a tightly regulated network of pathways controlling the biogenesis, folding, transport and degradation of proteins.

	The collaboration was launched with an upfront payment that enables us to evaluate selected targets and lead assets in protein homeostasis pathways during the pre-clinical phase. Based on such evaluation, we will have the right to obtain exclusive licenses with respect to the development and commercialization of multiple drug candidates outside of the United States, in exchange for research and early development payments of up to approximately $200.0 million to FORMA. Under the terms of the collaboration agreement, FORMA is incentivized to advance the full complement of drug candidates through Phase I, while Celgene will be responsible for all further global clinical development for each licensed candidate. FORMA is eligible to receive up to an additional $315.0 million in potential payments based upon development, regulatory and sales objectives for the first ex-U.S. license. FORMA is also eligible to receive potential payments for successive licenses, which escalate for productivity, increasing up to a maximum of an additional $430.0 million per program. In addition, FORMA will receive royalties on ex-U.S. sales and additional payments if multiple drug candidates reach defined cumulative sales objectives. The collaboration agreement includes provisions for Celgene to obtain rights with respect to development and commercialization of drug candidates inside the United States in exchange for additional payments.

	Under the collaboration, the parties will perform initial research and development for a term of four years. If, during such research term, a drug candidate meets certain criteria, then the parties will enter into a pre-negotiated license agreement and the collaboration will continue until all license agreements have expired and all applicable royalty terms under the collaboration with respect to the particular products have expired. Each license agreement, if not terminated sooner, would expire upon the expiration of all applicable royalty terms under such agreement. Upon the expiration of each license agreement, we will have an exclusive, fully-paid, royalty-free license to use the applicable FORMA intellectual property to manufacture, market, use and sell the product developed under such agreement outside of the United States. On October 7, 2013, we entered into the first ex-US license with FORMA and paid the applicable upfront payment under such license.

	On March 21, 2014, we entered into a second collaboration arrangement with FORMA, pursuant to which FORMA granted us an option for an additional fee to license the rights to select current and future FORMA drug candidates during a term of three and one half years. We agreed to pay an upfront payment of $225.0 million. In addition, with respect to each licensed drug candidate, we have the obligation to pay designated amounts when certain development, regulatory and sales milestone events occur, with such amounts being variable and contingent on various factors. With respect to each licensed drug candidate, we will assume responsibility for all global development activities and costs after completion of phase I clinical trials. FORMA will retain U.S. rights to all such licensed assets, including responsibility for manufacturing and commercialization.

	Under this collaboration arrangement, we also have an option to enter into up to two additional collaborations with successive terms of two years each for additional payments totaling approximately $375.0 million. If we exercise our option to enter into both of these additional collaborations, we will receive an exclusive option to acquire FORMA, including the U.S. rights to all licensed drug candidates, and worldwide rights to other wholly owned assets within FORMA at that time.
	NantBioScience, Inc. (NantBioScience): In January 2014, we entered into a collaboration agreement with NantBioScience, an entity controlled by Dr. Patrick Soon-Shiong in which Celgene contributed $75 million of cash, the rights to the future royalty stream based on net sales of certain products of Active Biomaterials, LLC, another entity controlled by Dr. Patrick Soon-Shiong, and licenses to two nab® product candidates. In return, Celgene received a 14 percent preferred equity ownership in NantBioScience, an option to license a certain number of product candidates developed by NantBioScience, including the two nab® product candidates that Celgene is licensing to NantBioScience, and the parent company of NantBioScience assumed, and agreed to pay and satisfy when due, our obligation to pay The Chan Soon-Shiong Institute for Advanced Health (CSS Institute) $50.0 million in contingent, matching contributions. The transaction became effective in March 2014. Unless Celgene terminates the collaboration earlier, in Celgene’s sole discretion upon 30 days written notice, the collaboration will continue until the earliest to occur of: (a) Celgene licensing four NantBioScience product candidates; (b) NantBioScience presenting data packages for ten product candidates; and (c) the date which is ten years after the effective date. Regardless of any termination of the collaboration, the 14 percent preferred equity ownership in NantBioScience and the assumption of the $50.0 million in contingent, matching contributions by the parent company of NantBioScience remain in effect. We performed a valuation of the components of the transaction and allocated the consideration transferred as follows: $50.0 million for the collaboration agreement upfront expense; $25.0 million related to the settlement of contingent matching contributions, and; $90.0 million related to the equity ownership in NantBioScience.
	In addition to the collaboration arrangements described above, we entered into new collaborative arrangements during the nine months ended September 30, 2014 that include the potential for future milestone payments of up to an aggregate of $52.5 million related to the attainment of specified developmental, regulatory and sales milestones over a period of several years. Our obligation to fund these efforts is contingent upon our continued involvement in the programs and/or the lack of any adverse events which could cause the discontinuance of the programs.
	A financial summary of certain period activity related to our collaboration agreements is presented below1,2:


			Three-Month Periods Ended September 30,
			Research and Development Expense						Selling, General and Administrative Expense
			Upfront Fees		Milestones		Amortization of Prepaid R&D and Intangibles		Selling, General and Administrative Expense		Equity Investments Made During Period
	Acceleron	2014	$—		$—		$—		$—		$—
		2013	—		—		—		—		10
	Acetylon	2014	—		—		4.3		—		—
		2013	50		—		0.6		—		10
	Agios	2014	—		—		—		—		—
		2013	—		—		—		—		12.8
	bluebird	2014	—		—		0.1		—		—
		2013	—		—		—		—		—
	Morphosys	2014	—		—		—		—		—
		2013	94.3		—		—		—		61.3
	Sutro(3)	2014	72.6		—		0.1		—		11.9
		2013	—		—		0.5		—		—
	Other Collaboration Arrangements	2014	6		6.8		0.4		—		27
		2013	27		—		0.8		—		—



			Nine-Month Periods Ended September 30,
			Research and Development Expense						Selling, General and Administrative Expense
			Upfront Fees		Milestones		Amortization of Prepaid R&D and Intangibles		Selling, General and Administrative Expense		Equity Investments Made During Period
Acceleron(4)	2014	$—		$—		$—		$—		$52.40
	2013	—		10		—		—		10
Acetylon	2014	—		—		11.4		—		—
	2013	50		—		0.6		—		10
Agios	2014	—		—		—		—		13
	2013	—		—		—		—		12.8
bluebird	2014	—		—		0.1		—		—
	2013	74.7		—		—		—		—
Epizyme	2014	—		—		—		—		9.9
	2013	—		—		—		—		1
FORMA	2014	225		—		0.1		—		—
	2013	23.8		—		—		—		—
Morphosys	2014	—		—		—		—		—
	2013	94.3		—		—		—		61.3
NantBioScience	2014	50		—		—		25		90
Sutro(3)	2014	72.6		—		0.2		—		11.9
	2013	—		—		1.6		—		—
Other Collaboration Arrangements	2014	54		7.3		6.9		—		47.9
	2013	106		1		1.7		—		8.9
A financial summary of the period-end balances related to our collaboration agreements is presented below:


	Balances as of:		Intangible Asset Balance		Equity Investment Balance		Percentage of Outstanding Equity
Acceleron	30-Sep-14		$—		$139.50		14%
	31-Dec-13		—		127.2		11%
Acetylon	30-Sep-14		24.3		25		10%
	31-Dec-13		35.7		25		10%
Agios	30-Sep-14		—		307.6		14%
	31-Dec-13		—		113		15%
bluebird	30-Sep-14		0.1		—		N/A
	31-Dec-13		0.2		—		N/A
Epizyme	30-Sep-14		—		99.6		11%
	31-Dec-13		—		69.4		12%
FORMA	30-Sep-14		0.1		—		N/A
	31-Dec-13		0.2		—		N/A
Morphosys	30-Sep-14		—		78.2		3%
	31-Dec-13		—		61.4		3%
NantBioScience	30-Sep-14		—		90		14%
Sutro(3)	30-Sep-14		12.8		17.6		15%
	31-Dec-13		2.5		5.7		6%
Other Collaboration Arrangements	30-Sep-14		32		78.3		N/A
	31-Dec-13		23.1		49.5		N/A

1	Activity and balances are presented specifically for notable new collaborations and for those collaborations which we have described in detail in our 2013 Annual Report on Form 10-K if there has been new activity during the periods presented. Amounts related to collaborations that are not specifically described are presented in the aggregate as Other Collaboration Arrangements.

2	In addition to the expenses noted in the tables above, we may also incur expenses for collaboration agreement related activities that are managed or funded by us.


3	Based on our assessment of the fair value of the components of the September 2014 agreement with Sutro, our payments of $95.0 million were allocated as $72.6 million of upfront collaboration expense, $11.9 million of equity investment asset, $9.0 million of manufacturing rights asset and $1.5 million of option to acquire asset.


4	Our additional equity investment in Acceleron made in the second quarter of 2014 was transacted at a price per share that exceeded the market value of Acceleron publicly traded common stock on the transaction closing date, resulting in an expense for the premium of $9.7 million that was recorded in the Consolidated Statements of Income as other income (expense), net in the second quarter of 2014.

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
Commitments and Contingencies	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	Commitments and Contingencies

	Collaboration Arrangements: We have entered into certain research and development collaboration agreements with third parties that include the funding of certain development, manufacturing and commercialization efforts with the potential for future milestone and royalty payments upon the achievement of pre-established developmental, regulatory and/or commercial targets. Our obligation to fund these efforts is contingent upon our continued involvement in the programs and/or the lack of any adverse events which could cause the discontinuance of the programs. Due to the nature and uncertainty of these arrangements and any future potential payments, no amounts have been recorded in our accompanying Consolidated Balance Sheets at September 30, 2014 and December 31, 2013. See Note 14 for additional details related to collaboration arrangements.

	Contingencies: We believe we maintain insurance coverage adequate for our current needs. Our operations are subject to environmental laws and regulations, which impose limitations on the discharge of pollutants into the air and water and establish standards for the treatment, storage and disposal of solid and hazardous wastes. We review the effects of such laws and regulations on our operations and modify our operations as appropriate. We believe we are in substantial compliance with all applicable environmental laws and regulations.

	We have ongoing customs, duties and VAT examinations in various countries that have yet to be settled. Based on our knowledge of the claims and facts and circumstances to date, none of these matters, individually or in the aggregate, are deemed to be material to our financial condition.

Legal_Proceedings

Legal Proceedings	9 Months Ended
Legal Proceedings	Sep. 30, 2014
Legal Proceedings	'
Legal Proceedings	'
	Legal Proceedings

	Like many companies in our industry, we have from time to time received inquiries and subpoenas and other types of information requests from government authorities and others and we have been subject to claims and other actions related to our business activities. While the ultimate outcome of investigations, inquires, information requests and legal proceedings is difficult to predict, adverse resolutions or settlements of those matters may result in, among other things, modification of our business practices, product recalls, costs and significant payments, which may have a material adverse effect on our results of operations, cash flows or financial condition.

	Pending patent proceedings include challenges to the scope, validity and/or enforceability of our patents relating to certain of our products, uses of products or processes. Further, we are subject to claims of third parties that we infringe their patents covering products or processes. Although we believe we have substantial defenses to these challenges and claims, there can be no assurance as to the outcome of these matters and an adverse decision in these proceedings could result in one or more of the following: (i) a loss of patent protection, which could lead to a significant reduction of sales that could materially affect future results of operations, (ii) our inability to continue to engage in certain activities, and (iii) significant liabilities, including payment of damages, royalties and/or license fees to any such third party.

	Among the principal matters pending are the following:

	Patent Related Proceedings:

	REVLIMID®: We received Notice Letters, dated August 30, 2010 and June 12, 2012 from Natco Pharma Limited of India (Natco) notifying us of Natco’s Abbreviated New Drug Application (ANDA), which contain Paragraph IV certifications against certain of Celgene’s patents that are listed in the FDA Approved Drug Products With Therapeutic Equivalence Evaluations (the “Orange Book”) for REVLIMID® (lenalidomide). Natco’s Notice Letters were sent in connection with its filing of an ANDA seeking permission from the FDA to market a generic version of 25mg, 15mg, 10mg and 5mg REVLIMID® capsules. We filed separate infringement actions (which were subsequently consolidated) in the United States District Court for the District of New Jersey against Natco, Natco’s U.S. partner, Arrow International Limited (Arrow), and Arrow’s parent company, Watson Laboratories, Inc. (Watson, a wholly-owned subsidiary of Actavis, Inc. and formerly known as Watson Pharmaceuticals, Inc.) (Natco, Arrow and Watson are collectively referred to hereinafter as “Natco”). In its answer and counterclaim, Natco asserts that our patents are invalid, unenforceable and/or not infringed by Natco’s proposed generic products. As a result of the filing of our actions, the FDA cannot grant final approval of Natco’s ANDA until the earlier of (i) a decision of the court that each of the patents is not infringed, invalid or unenforceable, or (ii) December 12, 2014.

	The patents in dispute include United States Patent Nos. 5,635,517; 6,045,501; 6,315,720; 6,555,554; 6,561,976; 6,561,977; 6,755,784; 7,119,106; 7,465,800; 6,281,230; 7,189,740; 7,968,569; 8,288,415; 8,315,886 and 8,404,717, plus three non-Orange Book listed patents, United States Patent Nos. 7,977,357; 8,193,219 and 8,431,598.

	A claim construction decision was issued on May 27, 2014. Fact discovery closed on August 4, 2014. On October 23, 2014, the court denied: (i) Natco’s motion to limit the patent claims asserted by Celgene and (ii) Natco’s motion to dismiss its inequitable-conduct claims and strike Celgene’s unclean-hands defense. In addition, the court granted Celgene’s motion to bifurcate and stay expert discovery pertaining to the REMS patents. All other expert discovery is ongoing. No trial date has been set.

	We believe that Natco’s defenses and counterclaims are unlikely to be sustained and we intend to vigorously assert our patent rights. Although there can be no assurance as to the ultimate outcome of this proceeding, we currently expect that it will not have a material adverse effect on our financial condition or results of operations. However, if Natco is successful in challenging all the patents in dispute or if the court rules that certain of our key patent claims are invalid or not infringed, such events could have a material adverse effect on our financial condition and results of operations.

	We received a third Notice Letter from Natco dated April 3, 2014, notifying us of Natco’s Paragraph IV certifications against five patents, including United States Patent Nos. 8,404,717 (already in suit), 8,530,498; 8,589,188; 8,626,531; and 8,648,095. On May 15, 2014, we filed an infringement action in the United States District Court for the District of New Jersey against Natco, Arrow and Watson. Natco filed its answer and counterclaim on June 13, 2014, and asserts that our patents are invalid, unenforceable and/or not infringed by Natco’s proposed generic products. A scheduling order has yet to be issued.

	ABRAXANE®: On December 14, 2011, Cephalon, Inc. and Acusphere, Inc. filed a complaint against us in the United States District Court for the District of Massachusetts, alleging, among other things, that the making, using, selling, offering to sell and importing of ABRAXANE® brand drug infringes claims of United States Patent No. RE40,493. The plaintiffs are seeking damages and injunctive relief. On December 3, 2013, the court issued an order construing certain claim terms. Based on that order, on March 18, 2014, the parties agreed to a judgment of noninfringement in Celgene’s favor. On April 15, 2014, the plaintiffs filed a Notice of Appeal to the United States Court of Appeals for the Federal Circuit seeking a review of the lower court’s construction of certain claim terms. On April 22, 2014 we filed a Notice of Cross-Appeal seeking review of certain terms defined in the lower court’s order.

	On May 23, 2014, the plaintiffs filed a motion to dismiss our cross-appeal, which motion was denied on June 30, 2014. On July 7, 2014, the plaintiffs filed an opening brief relating to the appeal. We filed our opening brief in August 18, 2014. Plaintiffs' reply brief is due on October 30, 2014 and our reply is due on November 6, 2014. Once briefing is complete, the Court will schedule a hearing on the appeal and cross-appeal.

	THALOMID® and REVLIMID®: On October 2, 2013, Andrulis Pharmaceuticals Corporation (Andrulis) filed a lawsuit against us in the United States District Court for the District of Delaware claiming infringement of U.S. Patent No. 6,140,346 (“the ‘346 patent”). Andrulis alleges that we are liable for infringement of one or more claims of the ‘346 patent, which covers the use of THALOMID® (and, as asserted by Andrulis, REVLIMID®) in combination with an alkylating agent (e.g., melphalan) to treat cancers. Andrulis is seeking an unspecified amount of damages, attorneys’ fees and injunctive relief. We disagree with Andrulis’ allegations and intend to vigorously defend against this infringement suit. On November 25, 2013, we filed a motion to dismiss Andrulis’ complaint. Andrulis’ motion seeking leave to file an amended complaint was granted on December 30, 2013. We filed a motion to dismiss Andrulis’ amended complaint on January 30, 2014. On April 11, 2014, the court denied our motion in part and granted our motion in part, dismissing two of Andrulis' four infringement claims without leave to amend. We filed an answer to the remaining claims on April 25, 2014. Fact discovery is set to close on June 16, 2015. A joint claim construction brief is due on March 30, 2015. A claim construction hearing is scheduled for April 30, 2015. Expert discovery is set to close on December 21, 2015. Trial is scheduled to begin on June 6, 2016. We do not expect the ultimate outcome of this lawsuit to have a material adverse effect on our financial condition or results of operations.
	ISTODAX® (romidepsin): We received a Notice Letter dated March 17, 2014 from Fresenius Kabi USA, LLC (Fresenius) notifying us of Fresenius’s ANDA that seeks approval from the FDA to market a generic version of romidepsin for injection. The Notice Letter contains Paragraph IV certifications against U.S. Patent Nos. 7,608,280 and 7,611,724 (the ‘280 and ‘724 patents) that are listed in the Orange Book for ISTODAX®.

	On April 30, 2014, Celgene and Astellas Pharma Inc., filed an infringement action in the United States District Court for the District of Delaware against Fresenius. In its answer and counterclaim, Fresenius asserts that the ‘280 and ‘724 patents are invalid and/or not infringed by its proposed generic products. As a result of the filing of our action, the FDA cannot grant final approval of Fresenius’s ANDA until the earlier of (i) a final decision that each of the patents is invalid and/or not infringed; or (ii) May 5, 2017.

	Fact discovery is set to close on August 7, 2015. A joint claim construction brief is due on August 7, 2015. A claim construction hearing is scheduled for September 3, 2015. Expert discovery is set to close on May 27, 2016. Trial is scheduled to begin on September 19, 2016.

	On August 4, 2014, we received a Notice Letter from InnoPharma, Inc. (InnoPharma) notifying us of Innopharma's ANDA that seeks approval from the FDA to market a generic version of romidepsin for injection. The Notice Letter contains Paragraph IV certifications against U.S. Patent Nos. 7,608,280 and 7,611,724 (the '280 and '724 patents) that are listed in the Orange Book for ISTODAX®.

	On September 12, 2014, Celgene and Astellas Pharma Inc., filed an infringement action in the United States District Court for the District of Delaware against InnoPharma. InnoPharma has not yet answered the complaint. As a result of the filing of our action, the FDA cannot grant final approval of InnoPharma's ANDA until the earlier of (i) a final decision that each of the patents is invalid and/or not infringed; or (ii) May 5, 2017.

	Other Proceedings:

	In 2009, we received a Civil Investigative Demand (CID) from the U.S. Federal Trade Commission (FTC) seeking documents and other information relating to requests by manufacturers of generic drugs to purchase our patented REVLIMID® and THALOMID® brand drugs in order for the FTC to evaluate whether there may be reason to believe that we have engaged in unfair methods of competition. In 2010, the State of Connecticut issued a subpoena referring to the same issues raised by the 2009 CID. Also in 2010, we received a second CID from the FTC relating to this matter. We continue to cooperate with the FTC and State of Connecticut investigations.

	On April 3, 2014, Mylan Pharmaceuticals Inc. (Mylan) filed a lawsuit against us in the United States District Court for the District of New Jersey alleging that we violated various federal and state antitrust and unfair competition laws by allegedly refusing to sell samples of our THALOMID® and REVLIMID® brand drugs so that Mylan can conduct the bioequivalence testing needed to submit ANDAs to the FDA for approval to market generic versions of these products. Mylan is seeking injunctive relief, damages and declaratory judgment. We filed a motion to dismiss Mylan’s complaint on May 25, 2014. Mylan filed its opposition to our motion to dismiss on June 16, 2014. The Federal Trade Commission filed an amicus curiae brief in opposition to our motion to dismiss on June 17, 2014. Oral arguments on our motion to dismiss is scheduled for December 12, 2014. A scheduling order has not yet been issued in this case. We intend to vigorously defend against Mylan’s claims.

	In 2011, the United States Attorney’s Office for the Central District of California informed us that they were investigating possible off-label marketing and improper payments to physicians in connection with the sales of THALOMID® and REVLIMID®. In 2012, we learned that two other United States Attorneys’ offices (the Northern District of Alabama and the Eastern District of Texas) and various state Attorneys General were conducting related investigations. In February 2014, three civil qui tam actions related to those investigations brought by three former Celgene employees on behalf of the federal and various state governments under the federal false claims act and similar state laws were unsealed after the United States Department of Justice (DOJ) declined to intervene in any of these actions. The DOJ retains the right to intervene in these actions at any time. Additionally, while several states have similarly declined to intervene in some of these actions, they also retain the right to intervene in the future. The plaintiffs in the Northern District of Alabama and Eastern District of Texas actions have voluntarily dismissed their cases. On April 25, 2014, we filed a motion to dismiss the complaint in the remaining (Central District of California) action (Brown Action). The plaintiff filed an opposition to our motion to dismiss on May 23, 2014. The DOJ as well as several state Attorneys General also filed Statements of Interest opposing certain arguments made in our motion to dismiss. The judge issued an order on July 10, 2014 largely denying our motion to dismiss, but granting in part our motion with respect to certain state claims. We filed our answer to the complaint on August 28, 2014. We intend to vigorously defend against the remaining claims in the Brown Action.
	In a related matter, in July 2014, we received a letter purportedly on behalf of two stockholders that demands, primarily on the basis of the allegations in the Brown Action, that our board of directors take action on the Company’s behalf to correct alleged deficiencies in the Company’s internal controls and to recover from current and past directors and officers damages those stockholders allege to have resulted from breaches of fiduciary duties related to the matters alleged in the Brown Action. Our Board has formed a Demand Investigation Committee of directors to consider the issues raised in the stockholders’ letter, and the committee has retained independent counsel to assist it.
	On June 7, 2013, Children's Medical Center Corporation (CMCC) filed a lawsuit against us in the Superior Court of the Commonwealth of Massachusetts alleging that our obligation to pay a 1% royalty on REVLIMID® net sales revenue and a 2.5% royalty on POMALYST®/IMNOVID® net sales revenue under a license agreement entered into in December 2002 extended beyond February 28, 2013 and that our failure to make royalty payments to CMCC subsequent to February 28, 2013 breached the license agreement. CMCC is seeking unspecified damages and a declaration that the license agreement remains in full force and effect. In July 2013, we removed these proceedings to the United States District Court for the District of Massachusetts. On August 5, 2013, we filed an answer to CMCC’s complaint and a counterclaim for declaratory judgment that our obligations to pay royalties have expired. On August 26, 2013, CMCC filed an answer to our counterclaim. A scheduling conference was held on February 11, 2014 and the court ordered fact discovery to be completed by December 15, 2014. No trial date has as yet been set by the court. On July 8, 2014, CR Rev Holdings, LLC (“CR Rev”) filed a complaint against Celgene in the same action. CR Rev alleges that CMCC sold and assigned a substantial portion of the royalty payments owed by Celgene on the sale of REVLIMID® to CR Rev. CR Rev has alleged identical causes of action with respect to REVLIMID® as those alleged by CMCC, and seeks unspecified damages and a declaration that the license agreement is still in effect. We intend to vigorously defend against CMCC's and CR Rev’s claims. As of September 30, 2014, we consider the range of reasonably possible loss relating to this lawsuit to be between zero and $72.4 million, with the high end of the range being the royalty payments on REVLIMID® we would have made to CMCC under the license agreement through September 30, 2014, if our obligation to pay royalties remained in effect. CMCC contends that our royalty obligation continues on net sales of REVLIMID®, as well as POMALYST®/IMNOVID®, at least until May 2016 and if CMCC prevails, we may be obligated to continue to pay royalties on sales for periods after September 30, 2014.

	In the second quarter of 2014, we received a Health Insurance Portability and Accountability Act (HIPAA) subpoena from the United States Attorney’s Office for the District of Massachusetts requesting certain documents relating to an investigators meeting in 2011 with respect to a clinical study relating to ABRAXANE®. The Company is cooperating with the United States Attorney in connection with this subpoena.

	In October 2014, a complaint was filed in Delaware Chancery Court by a stockholder asserting derivative claims on behalf of the Company against the non-employee members of the Board of Directors. The complaint alleges that equity grants made to non-employee directors in 2012 and 2013 were excessive compared to the equity grants to directors of peer companies, and that the award of such allegedly excessive compensation constituted a breach of fiduciary duty, waste of corporate assets, and unjust enrichment. The complaint seeks equitable relief, disgorgement of the alleged excess compensation, modification of the Company’s compensation process to limit the equity awards that may be granted to non-employee directors, and attorneys’ fees and other costs. The Company is a nominal defendant in the case. Neither the Company nor the individual defendants have yet responded to the complaint.

Acquisition_Tables

Acquisition (Tables)	9 Months Ended
	Sep. 30, 2014
Business Combinations [Abstract]	'
Consideration transferred	'
	The fair value of consideration transferred to acquire the license amounted to:


		Fair Value at the Acquisition Date
	Cash	$	710

	Contingent consideration	1,060.00

	Total fair value of consideration transferred	$	1,770.00

Purchase price allocation	'
	The purchase price allocation resulted in the following amounts being allocated to the assets acquired at the acquisition date based on their respective fair values:


		Fair Value at the Acquisition Date
	In-process research and development product rights	$	1,620.00

	Current deferred tax asset	1.3

	Non-current deferred tax liability	(1.3		)
	Total identifiable net assets	1,620.00

	Goodwill	150

	Total net assets acquired	$	1,770.00

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2014
Earnings Per Share [Abstract]	'
Schedule of earnings per share	'


		Three-Month Periods Ended September 30,				Nine-Month Periods Ended September 30,
	(Amounts in millions, except per share)	2014		2013		2014		2013
	Net income	$	508.5	$	372.5	$	1,386.00	$	1,235.50

	Weighted-average shares:
	Basic	799.6		824.5		803.5		829.5

	Effect of dilutive securities:
	Options, restricted stock units and other incentives	33.2		33.2		32.9		31.5

	Diluted	832.8		857.7		836.4		861

	Net income per share:
	Basic	$	0.64	$	0.45	$	1.72	$	1.49

	Diluted	$	0.61	$	0.43	$	1.66	$	1.43

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive Income (Loss) (Tables)	9 Months Ended
	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]	'
Summary of other comprehensive income (loss)	'
	The accumulated balances related to each component of other comprehensive income (loss), net of tax, are summarized as follows:


		Pension				Net Unrealized			Net Unrealized				Foreign				Total
		Liability				Gains (Losses) From			Gains (Losses)				Currency				Accumulated
						Marketable Securities			From Hedges				Translation				Other
													Adjustment				Comprehensive
																	Income (Loss)
	Balance December 31, 2013	$	(6.9	)		$	137.3		$	(36.0	)		$	(0.4	)		$	94

	Other comprehensive income (loss) before reclassifications	—				129.6			355.1				(32.5		)		452.2

	Amounts reclassified from accumulated other comprehensive income	—				2.7			3.6				—				6.3

	Net current-period other comprehensive income (loss)	—				132.3			358.7				(32.5		)		458.5

	Balance September 30, 2014	$	(6.9	)		$	269.6		$	322.7			$	(32.9	)		$	552.5



	Balance December 31, 2012	$	(10.1	)		$	4.2		$	(16.0	)		$	(27.8	)		$	(49.7	)

	Other comprehensive income (loss) before reclassifications	—				137.6			(3.2		)		22				156.4

	Amounts reclassified from accumulated other comprehensive income	—				4.4			(11.6		)		—				(7.2		)

	Net current-period other comprehensive income (loss)	—				142			(14.8		)		22				149.2

	Balance September 30, 2013	$	(10.1	)		$	146.2		$	(30.8	)		$	(5.8	)		$	99.5

Schedule of gains (losses) reclassified out of accumulated other comprehensive income	'


					Gains (Losses) Reclassified Out of Accumulated
					Other Comprehensive Income
	Accumulated Other Comprehensive Income Components		Affected Line Item in the Consolidated Statements of Income		Three-Month Periods Ended September 30,							Nine-Month Periods Ended September 30,
					2014			2013				2014				2013
	Gains (losses) from cash-flow hedges:
	Foreign exchange contracts		Net product sales		$	1.3		$	12			$	(1.7	)		$	7.6

	Treasury rate lock agreements		Interest (expense)		(0.9		)	(0.9		)		(2.6		)		(2.5		)
			Income tax benefit (expense)		—			0.3				—				6.5

	Interest rate swap agreements		Interest (expense)		(0.3		)	—				(0.5		)		—

			Income tax benefit (expense)		0.5			—				1.2				—


	Gains (losses) from available-for-sale marketable securities:
	Realized income (loss) on sales of marketable securities		Interest and investment income, net		(1.2		)	(3.0		)		(4.2		)		(6.2		)
			Income tax benefit (expense)		0.4			0.8				1.5				1.8

	Total reclassification, net of tax				$	(0.2	)	$	9.2			$	(6.3	)		$	7.2

Financial_Instruments_and_Fair1

Financial Instruments and Fair Value Measurement (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Disclosures [Abstract]	'
Assets and liabilities measured at fair value on recurring basis	'


		Balance at			Quoted Price in			Significant			Significant
		30-Sep-14			Active Markets for			Other Observable			Unobservable
					Identical Assets			Inputs			Inputs
					(Level 1)			(Level 2)			(Level 3)
	Assets:
	Available-for-sale securities	$	3,118.20		$	717.6		$	2,400.60		$	—

	Forward currency contracts	369.2			—			369.2			—

	Total assets	$	3,487.40		$	717.6		$	2,769.80		$	—

	Liabilities:

	Contingent value rights	$	(146.7	)	$	(146.7	)	$	—		$	—

	Interest rate swaps	(10.3		)	—			(10.3		)	—

	Other acquisition related contingent consideration	(1,250.9		)	—			—			(1,250.9		)

	Total liabilities	$	(1,407.9	)	$	(146.7	)	$	(10.3	)	$	(1,250.9	)

		Balance at			Quoted Price in			Significant			Significant
		December 31, 2013			Active Markets for			Other Observable			Unobservable
					Identical Assets			Inputs			Inputs
					(Level 1)			(Level 2)			(Level 3)
	Assets:

	Available-for-sale securities	$	2,452.60		$	433.1		$	2,019.50		$	—

	Cash equivalents	20			—			20			—

	Total assets	$	2,472.60		$	433.1		$	2,039.50		$	—

	Liabilities:

	Forward currency contracts	$	(9.2	)	$	—		$	(9.2	)	$	—

	Contingent value rights	(118.1		)	(118.1		)	—			—

	Interest rate swaps	(49.6		)	—			(49.6		)	—

	Other acquisition related contingent consideration	(228.5		)	—			—			(228.5		)

	Total liabilities	$	(405.4	)	$	(118.1	)	$	(58.8	)	$	(228.5	)
Roll-forward of fair value of Level 3 instruments (significant unobservable inputs), liabilities	'
	The following table represents a roll-forward of the fair value of Level 3 instruments:


		Nine-Month Periods Ended September 30,
		2014			2013
	Liabilities:

	Balance at beginning of period	$	(228.5	)	$	(198.1	)
	Amounts acquired or issued	(1,060.0		)	—

	Net change in fair value	17.6			(8.9		)

	Settlements	20			—

	Transfers in and/or out of Level 3	—			—

	Balance at end of period	$	(1,250.9	)	$	(207.0	)

Derivative_Instruments_and_Hed1

Derivative Instruments and Hedging Activities (Tables)

9 Months Ended

Sep. 30, 2014

Derivative Instruments and Hedging Activities

Schedule of fair value and balance sheet location of derivative instruments

The following tables summarize the fair value and presentation in the Consolidated Balance Sheets for derivative instruments as of September 30, 2014 and December 31, 2013:

30-Sep-14

Asset Derivatives

Liability Derivatives

Instrument

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments:

Foreign exchange contracts*

Other current assets

168.6

Other current assets

41.1

Other current liabilities

—

Other current liabilities

0.2

Other non-current assets

213.6

Other non-current assets

8.4

Other non-current liabilities

0.1

Other non-current liabilities

0.7

Interest rate swap agreements

Other current assets

15.8

Other current assets

—

Other non-current liabilities

—

Other non-current liabilities

27.5

Derivatives not designated as hedging instruments:

Foreign exchange contracts*

Other current assets

48.9

Other current assets

6.6

Other current liabilities

1.4

Other current liabilities

6.4

Interest rate swap agreements

Other non-current assets

1.4

Other non-current assets

—

Total

449.8

90.9

31-Dec-13

Asset Derivatives

Liability Derivatives

Instrument

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives designated as hedging instruments:

Foreign exchange contracts*

Other current assets

63.6

Other current assets

24.9

Other current liabilities

41.5

Other current liabilities

84.7

Other non-current assets

60.6

Other non-current assets

41.9

Other non-current liabilities

4.3

Other non-current liabilities

25.6

Interest rate swap agreements

Other current assets

17.1

Other current assets

—

Other non-current liabilities

—

Other non-current liabilities

68.3

Derivatives not designated as hedging instruments:

Foreign exchange contracts*

Other current assets

11.3

Other current assets

0.7

Other current liabilities

18.7

Interest rate swap agreements

Other current assets

0.1

Other current assets

—

Other non-current assets

1.5

Other non-current assets

—

Total

206

264.8

* Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20.

Cash flow hedges

Derivative Instruments and Hedging Activities

Schedule of effect of derivative instruments designated as hedging instruments on Consolidated Statements of Income

Three-Month Period Ended September 30, 2014

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Recognized in OCI

Reclassified from

Recognized in

on Derivative (1)

Accumulated OCI

Income on

into Income

Derivative

Instrument

(Effective Portion)

(Ineffective Portion

and Amount Excluded

From Effectiveness

Testing)

Foreign exchange contracts

382.8

Net product sales

1.3

Other income, net

(16.4

)

Treasury rate lock agreements

—

Interest expense

(0.9

)

Interest rate swap agreements

—

Interest expense

(0.3

)

(1) Net gains of $132.0 million are expected to be reclassified from Accumulated OCI into income in the next 12 months.

Three-Month Period Ended September 30, 2013

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Recognized in OCI

Reclassified from

Recognized in

on Derivative

Accumulated OCI

Income on

into Income

Derivative

Instrument

(Effective Portion)

(Ineffective Portion

and Amount Excluded

From Effectiveness

Testing)

Foreign exchange contracts

(89.8

)

Net product sales

11.9

Other income, net

5.1

-1

Treasury rate lock agreements

—

Interest expense

(0.9

)

Nine-Month Period Ended September 30, 2014

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Recognized in OCI

Reclassified from

Recognized in

on Derivative (1)

Accumulated OCI

Income on

into Income

Derivative

Instrument

(Effective Portion)

(Ineffective Portion

and Amount Excluded

From Effectiveness

Testing)

Foreign exchange contracts

374.9

Net product sales

(1.7

)

Other income, net

(19.2

)

Treasury rate lock agreements

—

Interest expense

(2.6

)

Interest rate swap agreements

(32.4

)

Interest expense

(0.5

)

Other income, net

(3.6

)

-3

(1) Net gains of $132.0 million are expected to be reclassified from Accumulated OCI into income in the next 12 months.

(3) The amount of net loss recognized in income relates to the ineffective portion of the hedging relationships.

Nine-Month Period Ended September 30, 2013

Amount of

Location of

Amount of

Location of

Amount of

Gain/(Loss)

Recognized in OCI

Reclassified from

Recognized in

on Derivative

Accumulated OCI

Income on

into Income

Derivative

Instrument

(Effective Portion)

(Ineffective Portion

and Amount Excluded

From Effectiveness

Testing)

Foreign exchange contracts

(3.2

)

Net product sales

7.6

Other income, net

)

Treasury rate lock agreements

—

Interest expense

(2.5

)

Fair value hedges

Derivative Instruments and Hedging Activities

Schedule of effect of derivative instruments designated as hedging instruments on Consolidated Statements of Income

Amount of Gain (Loss) Recognized in

Income on Derivative

Location of Gain (Loss) Recognized in Income on Derivative

Three-Month Periods Ended September 30,

Nine-Month Periods Ended September 30,

Instrument

2014

2013

2014

2013

Interest rate swap agreements

Interest expense

10.3

9.8

31.2

21.8

Amount of Gain (Loss) Recognized in

Income on Derivative

Location of Gain (Loss) Recognized in Income on Derivative

Three-Month Periods Ended September 30,

Nine-Month Periods Ended September 30,

Instrument

2014

2013

2014

2013

Foreign exchange contracts

Other income (expense), net

55.4

(27.0

)

44.3

(42.2

)

Put options on our common stock

Other income (expense), net

3.6

—

9.9

—

Foreign currency forward contracts

Derivative Instruments and Hedging Activities

Schedule of notional amount of derivative contracts

Foreign currency forward contracts entered into to hedge forecasted revenue and expenses were as follows at September 30, 2014 and December 31, 2013:

Notional Amount

Foreign Currency

30-Sep-14

31-Dec-13

Australian Dollar

19.7

—

British Pound

360.8

279.4

Canadian Dollar

79.9

—

Euro

3,437.70

3,318.20

Japanese Yen

567.8

559.1

Total

4,465.90

4,156.70

Interest rate swap contracts

Derivative Instruments and Hedging Activities

Schedule of notional amount of derivative contracts

The following table summarizes the notional amounts of our outstanding swap contracts at September 30, 2014 and December 31, 2013:

Notional Amount

30-Sep-14

31-Dec-13

Interest rate swap contracts entered into as fair value hedges of the following fixed-rate senior notes:

2.450% senior notes due 2015

300

1.900% senior notes due 2017

300

2.300% senior notes due 2018

200

2.250% senior notes due 2019

350

—

3.950% senior notes due 2020

500

3.250% senior notes due 2022

850

4.000% senior notes due 2023

100

150

Total

2,600.00

2,300.00

Cash_Cash_Equivalents_and_Mark1

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Tables)	9 Months Ended
	Sep. 30, 2014
Cash, Cash Equivalents, and Short-term Investments [Abstract]	'
Schedule of available-for-sale securities by major security type and class	'
	The amortized cost, gross unrealized holding gains, gross unrealized holding losses and estimated fair value of available-for-sale securities by major security type and class of security at September 30, 2014 and December 31, 2013 were as follows:


	30-Sep-14	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss			Estimated Fair Value
	U.S. Treasury securities	$	1,012.80	$	0.4	$	(0.7	)	$	1,012.50

	U.S. government-sponsored agency securities	195.5		0.2		(0.2		)	195.5

	U.S. government-sponsored agency MBS	556.4		0.7		(3.6		)	553.5

	Non-U.S. government, agency and Supranational securities	19.9		—		(0.1		)	19.8

	Corporate debt - global	438.8		1.1		(0.6		)	439.3

	Asset backed securities	180.2		—		(0.2		)	180

	Marketable equity securities	299.9		418.2		(0.5		)	717.6

	Total available-for-sale marketable securities	$	2,703.50	$	420.6	$	(5.9	)	$	3,118.20




	December 31, 2013	Amortized Cost		Gross Unrealized Gain		Gross Unrealized Loss			Estimated Fair Value
	U.S. Treasury securities	$	795.2	$	0.3	$	(0.4	)	$	795.1

	U.S. government-sponsored agency securities	208.9		0.2		(0.2		)	208.9

	U.S. government-sponsored agency MBS	450.8		0.1		(6.9		)	444

	Non-U.S. government, agency and Supranational securities	10.4		—		—			10.4

	Corporate debt - global	379.2		1.1		(0.6		)	379.7

	Asset backed securities	181.6		—		(0.2		)	181.4

	Marketable equity securities	212.9		220.2		—			433.1

	Total available-for-sale marketable securities	$	2,239.00	$	221.9	$	(8.3	)	$	2,452.60

Schedule of duration periods of available-for-sale debt securities	'
	Duration periods of available-for-sale debt securities at September 30, 2014 were as follows:



		Amortized		Fair
		Cost		Value
	Duration of one year or less	$	438.1	$	438.6

	Duration of one through three years	1,760.30		1,758.70

	Duration of three through five years	205.2		203.3

	Total	$	2,403.60	$	2,400.60

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Sep. 30, 2014
Inventory Disclosure [Abstract]	'
Summary of inventories by major category	'
	A summary of inventories by major category at September 30, 2014 and December 31, 2013 follows:


		30-Sep-14		31-Dec-13
	Raw materials	$	174	$	147.4

	Work in process	114.4		99.6

	Finished goods	83.6		93.4

	Total	$	372	$	340.4

Intangible_Assets_and_Goodwill1

Intangible Assets and Goodwill (Tables)	9 Months Ended
	Sep. 30, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of intangible assets by category	'
	The following summary of intangible assets by category includes intangibles currently being amortized and intangibles not yet subject to amortization:


	30-Sep-14	Gross Carrying Value		Accumulated Amortization			Intangible Assets, Net
	Amortizable intangible assets:

	Acquired developed product rights	$	3,405.90	$	(1,183.1	)	$	2,222.80

	Technology	333.7		(123.2		)	210.5

	Licenses	66.2		(17.0		)	49.2

	Other	42.6		(21.9		)	20.7

		3,848.40		(1,345.2		)	2,503.20

	Non-amortized intangible assets:

	Acquired IPR&D product rights	1,628.70		—			1,628.70

	Total intangible assets	$	5,477.10	$	(1,345.2	)	$	4,131.90


	31-Dec-13	Gross Carrying Value		Accumulated Amortization			Intangible Assets, Net
	Amortizable intangible assets:

	Acquired developed product rights	$	3,405.90	$	(1,026.4	)	$	2,379.50

	Technology	333.7		(87.4		)	246.3

	Licenses	66.2		(13.9		)	52.3

	Other	42.5		(18.8		)	23.7

		3,848.30		(1,146.5		)	2,701.80

	Non-amortized intangible assets:

	Acquired IPR&D product rights	137.9		—			137.9

	Total intangible assets	$	3,986.20	$	(1,146.5	)	$	2,839.70

Debt_Tables

Debt (Tables)	9 Months Ended
	Sep. 30, 2014
Debt Disclosure [Abstract]	'
Carrying values of the senior notes	'
	Summarized below are the carrying values of our senior notes at September 30, 2014 and December 31, 2013:



		30-Sep-14		31-Dec-13
	2.450% senior notes due 2015	$	508.2	$	513.9

	1.900% senior notes due 2017	500.3		499.9

	2.300% senior notes due 2018	400.1		399

	2.250% senior notes due 2019	498.8		—

	3.950% senior notes due 2020	495.4		484.6

	3.250% senior notes due 2022	991.1		956.6

	4.000% senior notes due 2023	704		696.3

	3.625% senior notes due 2024	996.7		—

	5.700% senior notes due 2040	249.6		249.6

	5.250% senior notes due 2043	396.6		396.6

	4.625% senior notes due 2044	996.5		—

	Total long-term debt	$	6,737.30	$	4,196.50

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Components of share-based compensation expense	'
	The following table summarizes the components of share-based compensation expense in the Consolidated Statements of Income for the three- and nine-month periods ended September 30, 2014 and 2013:



		Three-Month Periods Ended September 30,							Nine-Month Periods Ended September 30,
		2014			2013				2014		2013
	Cost of goods sold (excluding amortization of acquired intangible assets)	$	6.8		$	6.1			$	18.8	$	12.6

	Research and development	48.4			41.7				141.2		100.5

	Selling, general and administrative	56.2			44.2				159.2		114.3

	Total share-based compensation expense	111.4			92				319.2		227.4

	Tax benefit related to share-based compensation expense	31.4			29.9				92.4		66.1

	Reduction in income	$	80		$	62.1			$	226.8	$	161.3

Summary of activity for stock options, RSUs and PSUs	'
	The following table summarizes the activity for stock options, RSUs and PSUs for the nine-month period ended September 30, 2014 (in millions unless otherwise noted):


		Stock		Restricted Stock			Performance-
		Options		Units			Based Restricted
							Stock Units
							(in thousands)
	Outstanding at December 31, 2013	79.2		10.2			115

	Changes during the Year:

	Granted	10.6		1.8			48

	Exercised / Released	(9.6	)	(2.2	)		(24	)
	Forfeited	(1.3	)	(0.3	)		(6	)
	Outstanding at September 30, 2014	78.9		9.5			133

Schedule of unvested awards compensation cost not yet recognized and weighted-average periods for recognition	'
	Total compensation cost related to unvested awards not yet recognized and the weighted-average periods over which the awards are expected to be recognized at September 30, 2014 were as follows (dollars in millions):


		Stock			Restricted Stock				Performance-
		Options			Units				Based Restricted
									Stock Units
	Unrecognized compensation cost	$	500.3		$	277.8			$	6.3

	Expected weighted-average period in years of compensation cost to be recognized	2.1			1.3				1.8

Collaboration_Agreements_Table

Collaboration Agreements (Tables)	9 Months Ended
Collaboration Agreements (Tables)	Sep. 30, 2014
Collaboration Agreements [Abstract]	'
Schedule of Collaboration Agreements	'
	A financial summary of certain period activity related to our collaboration agreements is presented below1,2:


			Three-Month Periods Ended September 30,
			Research and Development Expense						Selling, General and Administrative Expense
			Upfront Fees		Milestones		Amortization of Prepaid R&D and Intangibles		Selling, General and Administrative Expense	Equity Investments Made During Period
	Acceleron	2014	$—		$—		$—		$—	$—
		2013	—		—		—		—	10
	Acetylon	2014	—		—		4.3		—	—
		2013	50		—		0.6		—	10
	Agios	2014	—		—		—		—	—
		2013	—		—		—		—	12.8
	bluebird	2014	—		—		0.1		—	—
		2013	—		—		—		—	—
	Morphosys	2014	—		—		—		—	—
		2013	94.3		—		—		—	61.3
	Sutro(3)	2014	72.6		—		0.1		—	11.9
		2013	—		—		0.5		—	—
	Other Collaboration Arrangements	2014	6		6.8		0.4		—	27
		2013	27		—		0.8		—	—



			Nine-Month Periods Ended September 30,
			Research and Development Expense						Selling, General and Administrative Expense
			Upfront Fees		Milestones		Amortization of Prepaid R&D and Intangibles		Selling, General and Administrative Expense	Equity Investments Made During Period
	Acceleron(4)	2014	$—		$—		$—		$—	$52.40
		2013	—		10		—		—	10
	Acetylon	2014	—		—		11.4		—	—
		2013	50		—		0.6		—	10
	Agios	2014	—		—		—		—	13
		2013	—		—		—		—	12.8
	bluebird	2014	—		—		0.1		—	—
		2013	74.7		—		—		—	—
	Epizyme	2014	—		—		—		—	9.9
		2013	—		—		—		—	1
	FORMA	2014	225		—		0.1		—	—
		2013	23.8		—		—		—	—
	Morphosys	2014	—		—		—		—	—
		2013	94.3		—		—		—	61.3
	NantBioScience	2014	50		—		—		25	90
	Sutro(3)	2014	72.6		—		0.2		—	11.9
		2013	—		—		1.6		—	—
	Other Collaboration Arrangements	2014	54		7.3		6.9		—	47.9
		2013	106		1		1.7		—	8.9
	A financial summary of the period-end balances related to our collaboration agreements is presented below:


		Balances as of:		Intangible Asset Balance		Equity Investment Balance		Percentage of Outstanding Equity
	Acceleron	30-Sep-14		$—		$139.50		14%
		31-Dec-13		—		127.2		11%
	Acetylon	30-Sep-14		24.3		25		10%
		31-Dec-13		35.7		25		10%
	Agios	30-Sep-14		—		307.6		14%
		31-Dec-13		—		113		15%
	bluebird	30-Sep-14		0.1		—		N/A
		31-Dec-13		0.2		—		N/A
	Epizyme	30-Sep-14		—		99.6		11%
		31-Dec-13		—		69.4		12%
	FORMA	30-Sep-14		0.1		—		N/A
		31-Dec-13		0.2		—		N/A
	Morphosys	30-Sep-14		—		78.2		3%
		31-Dec-13		—		61.4		3%
NantBioScience	30-Sep-14		—		90		14%
Sutro(3)	30-Sep-14		12.8		17.6		15%
	31-Dec-13		2.5		5.7		6%
Other Collaboration Arrangements	30-Sep-14		32		78.3		N/A
	31-Dec-13		23.1		49.5		N/A

1	Activity and balances are presented specifically for notable new collaborations and for those collaborations which we have described in detail in our 2013 Annual Report on Form 10-K if there has been new activity during the periods presented. Amounts related to collaborations that are not specifically described are presented in the aggregate as Other Collaboration Arrangements.

2	In addition to the expenses noted in the tables above, we may also incur expenses for collaboration agreement related activities that are managed or funded by us.


3	Based on our assessment of the fair value of the components of the September 2014 agreement with Sutro, our payments of $95.0 million were allocated as $72.6 million of upfront collaboration expense, $11.9 million of equity investment asset, $9.0 million of manufacturing rights asset and $1.5 million of option to acquire asset.


4	Our additional equity investment in Acceleron made in the second quarter of 2014 was transacted at a price per share that exceeded the market value of Acceleron publicly traded common stock on the transaction closing date, resulting in an expense for the premium of $9.7 million that was recorded in the Consolidated Statements of Income as other income (expense), net in the second quarter of 2014.

Nature_of_Business_and_Basis_o1

Nature of Business and Basis of Presentation (Details)	0 Months Ended	9 Months Ended
Nature of Business and Basis of Presentation (Details)	Feb. 12, 2014	Sep. 30, 2014	Jun. 18, 2014	Jun. 17, 2014	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'	'	'	'	'
Maximum equity ownership percentage, investments	'	50.00%	'	'	'
Stock split, conversion ratio	2	'	'	'	'
Common stock, shares authorized	'	1,150,000,000	1,150,000,000	575,000,000	1,150,000,000

Acquisition_Details

Acquisition (Details) (USD $)	9 Months Ended			0 Months Ended				0 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013	14-May-14	14-May-14	Sep. 30, 2014	Sep. 30, 2014	14-May-14
				GED-0301	GED-0301	GED-0301	GED-0301	GED-0301
						Other current liabilities	Other non-current liabilities	Maximum
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'
Potential milestone payment	'	'	'	'	$815	'	'	'
Global annual sales	'	'	'	500	'	'	'	4,000
Potential tiered sales milestones	'	'	'	1,050	'	'	'	'
Consideration Transferred:	'	'	'	'	'	'	'	'
Cash	710	0	'	710	'	'	'	'
Contingent consideration	'	'	'	'	1,060	5	1,055	'
Total fair value of consideration transferred	'	'	'	1,770	'	'	'	'
Assets Acquired and Liabilities Assumed:	'	'	'	'	'	'	'	'
In-process research and development product rights	'	'	'	'	1,620	'	'	'
Current deferred tax asset	'	'	'	'	1.3	'	'	'
Non-current deferred tax liability	'	'	'	'	-1.3	'	'	'
Total identifiable net assets	'	'	'	'	1,620	'	'	'
Goodwill	2,191.20	'	2,041.20	'	150	'	'	'
Total net assets acquired	'	'	'	'	$1,770	'	'	'

Earnings_Per_Share_Details

Earnings Per Share (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
Earnings Per Share (Details) (USD $)	Apr. 28, 2014	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]	'	'	'	'	'
Net income	'	$508,500,000	$372,500,000	$1,386,000,000	$1,235,500,000
Weighted-average shares:	'	'	'	'	'
Basic (in shares)	'	799,600,000	824,500,000	803,500,000	829,500,000
Effect of dilutive securities:	'	'	'	'	'
Options, restricted stock units and other incentives	'	33,200,000	33,200,000	32,900,000	31,500,000
Diluted (in shares)	'	832,800,000	857,700,000	836,400,000	861,000,000
Net income per share:	'	'	'	'	'
Basic (in dollars per share)	'	$0.64	$0.45	$1.72	$1.49
Diluted (in dollars per share)	'	$0.61	$0.43	$1.66	$1.43
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Antidilutive securities excluded from computation of earnings per share (in shares)	'	13,700,000	8,200,000	17,900,000	10,200,000
Approved common share repurchase amount	4,000,000,000	'	'	13,500,000,000	'
Shares repurchased under share repurchase program (in shares)	'	2,800,000	'	16,700,000	'
Shares repurchased under share repurchase program	'	251,600,000	'	2,388,000,000	'
Remaining authorized repurchase amount under stock purchase program	'	'	'	3,680,000,000	'
Put option	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Notional amount	'	200,000,000	'	200,000,000	'
Put option premium	'	'	'	9,900,000	'
Put options outstanding	'	0	'	0	'
Put option \| Other income (expense)	'	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'	'
Gain on put option premium	'	'	'	$3,600,000	'

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive Income (Loss) (Components of AOCI) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Balance at the beginning of the period	'	'	$94	($49.70)
Other comprehensive income (loss) before reclassifications	'	'	452.2	156.4
Amounts reclassified from accumulated other comprehensive income	'	'	6.3	-7.2
Total other comprehensive income (loss)	388.8	23.7	458.5	149.2
Balance at the end of the period	552.5	99.5	552.5	99.5
Pension Liability	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Balance at the beginning of the period	'	'	-6.9	-10.1
Other comprehensive income (loss) before reclassifications	'	'	0	0
Amounts reclassified from accumulated other comprehensive income	'	'	0	0
Total other comprehensive income (loss)	'	'	0	0
Balance at the end of the period	-6.9	-10.1	-6.9	-10.1
Net Unrealized Gains (Losses) From Marketable Securities	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Balance at the beginning of the period	'	'	137.3	4.2
Other comprehensive income (loss) before reclassifications	'	'	129.6	137.6
Amounts reclassified from accumulated other comprehensive income	'	'	2.7	4.4
Total other comprehensive income (loss)	'	'	132.3	142
Balance at the end of the period	269.6	146.2	269.6	146.2
Net Unrealized Gains (Losses) From Hedges	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Balance at the beginning of the period	'	'	-36	-16
Other comprehensive income (loss) before reclassifications	'	'	355.1	-3.2
Amounts reclassified from accumulated other comprehensive income	'	'	3.6	-11.6
Total other comprehensive income (loss)	'	'	358.7	-14.8
Balance at the end of the period	322.7	-30.8	322.7	-30.8
Foreign Currency Translation Adjustment	'	'	'	'
Accumulated Other Comprehensive Income (Loss) [Roll Forward]	'	'	'	'
Balance at the beginning of the period	'	'	-0.4	-27.8
Other comprehensive income (loss) before reclassifications	'	'	-32.5	22
Amounts reclassified from accumulated other comprehensive income	'	'	0	0
Total other comprehensive income (loss)	'	'	-32.5	22
Balance at the end of the period	($32.90)	($5.80)	($32.90)	($5.80)

Accumulated_Other_Comprehensiv3

Accumulated Other Comprehensive Income (Loss) (Reclassification of AOCI) (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Other Comprehensive Income (Loss)	'	'	'	'
Net product sales	$1,956.80	$1,644	$5,508.90	$4,637.40
Interest (expense)	-53.5	-24	-124.4	-61.5
Income tax benefit (expense)	-69	-69.5	-230.6	-212.7
Interest and investment income, net	6.9	5.3	20.6	14.6
Net income	508.5	372.5	1,386	1,235.50
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income	'	'	'	'
Other Comprehensive Income (Loss)	'	'	'	'
Net income	-0.2	9.2	-6.3	7.2
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income \| Gains (losses) from cash-flow hedges: \| Foreign exchange contracts	'	'	'	'
Other Comprehensive Income (Loss)	'	'	'	'
Net product sales	1.3	12	-1.7	7.6
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income \| Gains (losses) from cash-flow hedges: \| Treasury rate lock agreements	'	'	'	'
Other Comprehensive Income (Loss)	'	'	'	'
Interest (expense)	-0.9	-0.9	-2.6	-2.5
Income tax benefit (expense)	0	0.3	0	6.5
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income \| Gains (losses) from cash-flow hedges: \| Interest rate swap agreements	'	'	'	'
Other Comprehensive Income (Loss)	'	'	'	'
Interest (expense)	-0.3	0	-0.5	0
Income tax benefit (expense)	0.5	0	1.2	0
Gains (Losses) Reclassified Out of Accumulated Other Comprehensive Income \| Gains (losses) from available-for-sale marketable securities:	'	'	'	'
Other Comprehensive Income (Loss)	'	'	'	'
Income tax benefit (expense)	0.4	0.8	1.5	1.8
Interest and investment income, net	($1.20)	($3)	($4.20)	($6.20)

Financial_Instruments_and_Fair2

Financial Instruments and Fair Value Measurement (Details) (USD $)

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Recurring basis

Gloucester Pharmaceuticals, Inc.

Avila Therapeutics, Inc.

Nogra

Fair Value

Net change in fair value

Quoted Price in Active Markets for Identical Assets (Level 1)

Significant Other Observable Inputs (Level 2)

Significant Unobservable Inputs (Level 3)

Maximum

Recurring basis

Licenses

Fair Value of assets and liabilities

Potential milestone payment

$120

$575

$1,865

Net increase during period

1,022

1,060

Change in value of contingent consideration

-11

-79.5

Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings

17.6

-8.9

17.6

Assets:

Available-for-sale securities

717.6

433.1

2,400.60

2,019.50

3,118.20

2,452.60

Forward currency contracts

369.2

Cash equivalents

Total assets

717.6

433.1

2,769.80

2,039.50

3,487.40

2,472.60

Liabilities:

Forward currency contracts

-9.2

Contingent value rights

-146.7

-118.1

-146.7

-118.1

Interest rate swaps

-10.3

-49.6

-10.3

-49.6

Other acquisition related contingent consideration

-1,250.90

-228.5

-1,250.90

-228.5

-58

Total liabilities

($146.70)

($118.10)

($10.30)

($58.80)

($1,250.90)

($228.50)

($1,407.90)

($405.40)

Financial_Instruments_and_Fair3

Financial Instruments and Fair Value Measurement (Details 2) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Fair Value Disclosures [Abstract]	'	'
Amount of transfer of assets out of Level 1 into Level 2	$0	$0
Amount of transfer of assets out of Level 2 into Level 1	0	0
Amount of transfer of liabilities out of Level 1 into Level 2	0	0
Amount of transfer of liabilities out of Level 2 into Level 1	0	0
Roll forward of fair value of Level 3 instruments (significant unobservable inputs), Liabilities:	'	'
Balance at beginning of period	-228,500,000	-198,100,000
Amounts acquired or issued	-1,060,000,000	0
Net change in fair value	17,600,000	-8,900,000
Settlements	20,000,000	0
Transfers in and/or out of Level 3	0	0
Balance at end of period	($1,250,900,000)	($207,000,000)

Derivative_Instruments_and_Hed2

Derivative Instruments and Hedging Activities (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

In Millions, unless otherwise specified

2.450% senior notes due 2015

1.900% senior notes due 2017

3.950% senior notes due 2020

3.250% senior notes due 2022

4.000% senior notes due 2023

Senior notes

Foreign currency forward contracts

Treasury rate lock agreements

Designated as hedging instruments

Not designated as hedging instruments

2.450% senior notes due 2015

1.900% senior notes due 2017

2.300% senior notes due 2018

2.250% senior notes due 2019

3.950% senior notes due 2020

3.250% senior notes due 2022

4.000% senior notes due 2023

Foreign currency forward contracts

Interest rate swap contracts

Foreign currency forward contracts

Cash flow hedges

Australian Dollar

British Pound

Canadian Dollar

Euro

Japanese Yen

Senior notes

Cash flow hedges

Other income, net

2.450% senior notes due 2015

1.900% senior notes due 2017

2.300% senior notes due 2018

2.250% senior notes due 2019

3.950% senior notes due 2020

3.250% senior notes due 2022

4.000% senior notes due 2023

Derivative Instruments and Hedging Activities

Period to settlement dates of derivatives is within this period

'3 years

'36 months

Notional amount

$4,465.90

$4,156.70

$19.70

$360.80

$279.40

$79.90

$3,437.70

$3,318.20

$567.80

$559.10

$2,600

$2,300

$300

$200

$350

$500

$850

$100

$150

$897.20

$878.50

Notional amount entered into during period

1,500

Gains (losses) on ineffective portion

3.6

Losses recorded to AOCI

53.3

-25.9

Interest rate (as a percent)

2.45%

1.90%

3.95%

3.25%

4.00%

2.45%

1.90%

2.30%

2.25%

3.95%

3.25%

4.00%

Proceeds from settlement of interest rate swap contracts

$15.30

$21.90

Derivative_Instruments_and_Hed3

Derivative Instruments and Hedging Activities (Details 2) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013	Dec. 31, 2013
Fair value of derivative instruments	'		'	'
Asset derivative	$449.80		'	$206
Liability derivative	90.9		'	264.8
Designated as hedging instruments \| Foreign exchange contracts	'		'	'
Summary of fair value and presentation in the consolidated balance sheets for derivative instruments	'		'	'
Notional amount	4,465.90		'	4,156.70
Designated as hedging instruments \| Foreign exchange contracts \| Other current assets	'		'	'
Fair value of derivative instruments	'		'	'
Asset derivative	168.6	[1]	'	63.6	[1]
Liability derivative	41.1	[1]	'	24.9	[1]
Designated as hedging instruments \| Foreign exchange contracts \| Other current liabilities	'		'	'
Fair value of derivative instruments	'		'	'
Asset derivative	0	[1]	'	41.5	[1]
Liability derivative	0.2	[1]	'	84.7	[1]
Designated as hedging instruments \| Foreign exchange contracts \| Other non-current assets	'		'	'
Fair value of derivative instruments	'		'	'
Asset derivative	213.6	[1]	'	60.6	[1]
Liability derivative	8.4	[1]	'	41.9	[1]
Designated as hedging instruments \| Foreign exchange contracts \| Other non-current liabilities	'		'	'
Fair value of derivative instruments	'		'	'
Asset derivative	'		'	4.3	[1]
Asset derivative	0.1	[1]	'	'
Liability derivative	0.7	[1]	'	'
Liability derivative	'		'	25.6	[1]
Designated as hedging instruments \| Interest rate swap agreements	'		'	'
Summary of fair value and presentation in the consolidated balance sheets for derivative instruments	'		'	'
Notional amount	2,600		'	2,300
Proceeds from settlement of interest rate swap contracts	15.3		21.9	'
Designated as hedging instruments \| Interest rate swap agreements \| Other current assets	'		'	'
Fair value of derivative instruments	'		'	'
Asset derivative	15.8		'	17.1
Liability derivative	0		'	0
Designated as hedging instruments \| Interest rate swap agreements \| Other non-current liabilities	'		'	'
Fair value of derivative instruments	'		'	'
Asset derivative	0		'	0
Liability derivative	27.5		'	68.3
Not designated as hedging instruments \| Foreign exchange contracts	'		'	'
Summary of fair value and presentation in the consolidated balance sheets for derivative instruments	'		'	'
Notional amount	897.2		'	878.5
Not designated as hedging instruments \| Foreign exchange contracts \| Other current assets	'		'	'
Fair value of derivative instruments	'		'	'
Asset derivative	48.9	[1]	'	11.3	[1]
Liability derivative	6.6	[1]	'	0.7	[1]
Not designated as hedging instruments \| Foreign exchange contracts \| Other current liabilities	'		'	'
Fair value of derivative instruments	'		'	'
Asset derivative	1.4	[1]	'	6	[1]
Liability derivative	6.4	[1]	'	18.7	[1]
Not designated as hedging instruments \| Interest rate swap agreements \| Other current assets	'		'	'
Fair value of derivative instruments	'		'	'
Asset derivative	'		'	0.1
Liability derivative	'		'	0
Not designated as hedging instruments \| Interest rate swap agreements \| Other non-current assets	'		'	'
Fair value of derivative instruments	'		'	'
Asset derivative	1.4	[1]	'	1.5
Liability derivative	0		'	'
Liability derivative	'		'	$0

[1]	Derivative instruments in this category are subject to master netting arrangements and are presented on a net basis in the Consolidated Balance Sheets in accordance with ASC 210-20.

Derivative_Instruments_and_Hed4

Derivative Instruments and Hedging Activities (Details 3) (USD $)	3 Months Ended				9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014		Sep. 30, 2013		Sep. 30, 2014		Sep. 30, 2013
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Gains (losses) expected to be reclassified from accumulated OCI into operations in the next 12 months	$132		'		$132		'
Not designated as hedging instruments \| Foreign exchange contracts \| Other income, net	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Recognized in OCI on Derivative (Effective Portion)	55.4		-27		44.3		-42.2
Not designated as hedging instruments \| Treasury rate lock agreements \| Other income, net	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Recognized in OCI on Derivative (Effective Portion)	3.6		0		9.9		0
Designated as hedging instruments \| Cash flow hedges \| Foreign exchange contracts	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Recognized in OCI on Derivative (Effective Portion)	382.8	[1]	-89.8		374.9		-3.2
Designated as hedging instruments \| Cash flow hedges \| Foreign exchange contracts \| Net product sales	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	1.3		11.9		-1.7		7.6
Designated as hedging instruments \| Cash flow hedges \| Foreign exchange contracts \| Other income, net	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Recognized in Income on Derivative	-16.4	[2]	5.1	[3]	-19.2	[2]	9	[4]
Gains (losses) on ineffective portion	'		3.6		'		'
Gains (losses) related to amounts excluded from assessment of hedge effectiveness	-18.6		5.3		-22.1		7.3
Gains (losses) related to the ineffective portion of the hedging relationships	2.2		-0.2		2.9		1.7
Designated as hedging instruments \| Cash flow hedges \| Treasury rate lock agreements	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Recognized in OCI on Derivative (Effective Portion)	0	[1]	0		0		0
Designated as hedging instruments \| Cash flow hedges \| Treasury rate lock agreements \| Interest expense	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	-0.9		-0.9		-2.6		-2.5
Designated as hedging instruments \| Cash flow hedges \| Interest rate swap contracts	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Recognized in OCI on Derivative (Effective Portion)	0	[1]	'		-32.4		'
Designated as hedging instruments \| Cash flow hedges \| Interest rate swap contracts \| Other income, net	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Recognized in Income on Derivative	'		'		-3.6	[5]	'
Designated as hedging instruments \| Cash flow hedges \| Interest rate swap contracts \| Interest expense	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Reclassified from Accumulated OCI into Income (Effective Portion)	-0.3		'		-0.5		'
Designated as hedging instruments \| Fair value hedges \| Interest rate swap contracts \| Interest expense	'		'		'		'
Effect of derivative instruments on Consolidated Statements of Income	'		'		'		'
Amount of Gain/(Loss) Recognized in Income on Derivative	$10.30		$9.80		$31.20		$21.80

[1]	Net gains of $132.0 million are expected to be reclassified from Accumulated OCI into income in the next 12 months.
[2]	The amount of net losses recognized in income represents $18.6 million of losses related to amounts excluded from the assessment of hedge effectiveness (fair value adjustments of forward point amounts) and $2.2 million in gains related to the ineffective portion of the hedging relationships.
[3]	The amount of net gains recognized in income represents $5.3 million of gains related to amounts excluded from the assessment of hedge effectiveness and $0.2 million of losses related to the ineffective portion of the hedging relationships.
[4]	The amount of net gains recognized in income represents $7.3 million of gains related to amounts excluded from the assessment of hedge effectiveness and $1.7 million in gains related to the ineffective portion of the hedging relationships.
[5]	The amount of net loss recognized in income relates to the ineffective portion of the hedging relationships.

Cash_Cash_Equivalents_and_Mark2

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Cash and cash equivalents	'	'
Money market funds	$2,285	$1,697
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	2,703.50	2,239
Gross Unrealized Gain	420.6	221.9
Gross Unrealized Loss	-5.9	-8.3
Estimated Fair Value	3,118.20	2,452.60
U.S. Treasury securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	1,012.80	795.2
Gross Unrealized Gain	0.4	0.3
Gross Unrealized Loss	-0.7	-0.4
Estimated Fair Value	1,012.50	795.1
U.S. government-sponsored agency securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	195.5	208.9
Gross Unrealized Gain	0.2	0.2
Gross Unrealized Loss	-0.2	-0.2
Estimated Fair Value	195.5	208.9
U.S. government-sponsored agency MBS	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	556.4	450.8
Gross Unrealized Gain	0.7	0.1
Gross Unrealized Loss	-3.6	-6.9
Estimated Fair Value	553.5	444
Non-U.S. government, agency and Supranational securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	19.9	10.4
Gross Unrealized Gain	0	0
Gross Unrealized Loss	-0.1	0
Estimated Fair Value	19.8	10.4
Corporate debt - global	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	438.8	379.2
Gross Unrealized Gain	1.1	1.1
Gross Unrealized Loss	-0.6	-0.6
Estimated Fair Value	439.3	379.7
Asset backed securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	180.2	181.6
Gross Unrealized Gain	0	0
Gross Unrealized Loss	-0.2	-0.2
Estimated Fair Value	180	181.4
Marketable equity securities	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Amortized Cost	299.9	212.9
Gross Unrealized Gain	418.2	220.2
Gross Unrealized Loss	-0.5	0
Estimated Fair Value	$717.60	$433.10

Cash_Cash_Equivalents_and_Mark3

Cash, Cash Equivalents and Marketable Securities Available-for-Sale (Details 2) (USD $)	Sep. 30, 2014
In Millions, unless otherwise specified	Sep. 30, 2014
Amortized Cost	'
Duration of one year or less	$438.10
Duration of one through three years	1,760.30
Duration of three through five years	205.2
Total	2,403.60
Fair Value	'
Duration of one year or less	438.6
Duration of one through three years	1,758.70
Duration of three through five years	203.3
Total	$2,400.60

Inventory_Details

Inventory (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Inventory Disclosure [Abstract]	'	'
Raw materials	$174	$147.40
Work in process	114.4	99.6
Finished goods	83.6	93.4
Total	$372	$340.40

Intangible_Assets_and_Goodwill2

Intangible Assets and Goodwill (Details) (USD $)	3 Months Ended		9 Months Ended
Intangible Assets and Goodwill (Details) (USD $)	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Intangible Assets By Category	'	'	'	'	'
Gross Carrying Value	$3,848,400,000	'	$3,848,400,000	'	$3,848,300,000
Accumulated Amortization	-1,345,200,000	'	-1,345,200,000	'	-1,146,500,000
Intangible Assets, Net	2,503,200,000	'	2,503,200,000	'	2,701,800,000
Weighted Average Life	'	'	'11 years 4 months	'	'
Total intangible assets	'	'	'	'	'
Gross Carrying Value	5,477,100,000	'	5,477,100,000	'	3,986,200,000
Intangible Assets, Net	4,131,900,000	'	4,131,900,000	'	2,839,700,000
Acquired intangible assets	'	'	1,491,000,000	'	'
Amortization of acquired intangible assets	65,000,000	67,500,000	198,800,000	201,600,000	'
Summary of changes in carrying value of goodwill	'	'	'	'	'
Goodwill	2,191,200,000	'	2,191,200,000	'	2,041,200,000
Nogra	'	'	'	'	'
Summary of changes in carrying value of goodwill	'	'	'	'	'
Goodwill, acquired during period	'	'	150,000,000	'	'
Acquired developed product rights	'	'	'	'	'
Intangible Assets By Category	'	'	'	'	'
Gross Carrying Value	3,405,900,000	'	3,405,900,000	'	3,405,900,000
Accumulated Amortization	-1,183,100,000	'	-1,183,100,000	'	-1,026,400,000
Intangible Assets, Net	2,222,800,000	'	2,222,800,000	'	2,379,500,000
Technology	'	'	'	'	'
Intangible Assets By Category	'	'	'	'	'
Gross Carrying Value	333,700,000	'	333,700,000	'	333,700,000
Accumulated Amortization	-123,200,000	'	-123,200,000	'	-87,400,000
Intangible Assets, Net	210,500,000	'	210,500,000	'	246,300,000
Licenses	'	'	'	'	'
Intangible Assets By Category	'	'	'	'	'
Gross Carrying Value	66,200,000	'	66,200,000	'	66,200,000
Accumulated Amortization	-17,000,000	'	-17,000,000	'	-13,900,000
Intangible Assets, Net	49,200,000	'	49,200,000	'	52,300,000
Total intangible assets	'	'	'	'	'
Impairment of intangible assets (excluding goodwill)	'	'	129,200,000	'	'
Licenses \| Nogra	'	'	'	'	'
Total intangible assets	'	'	'	'	'
Acquired intangible assets	'	'	1,620,000,000	'	'
Other	'	'	'	'	'
Intangible Assets By Category	'	'	'	'	'
Gross Carrying Value	42,600,000	'	42,600,000	'	42,500,000
Accumulated Amortization	-21,900,000	'	-21,900,000	'	-18,800,000
Intangible Assets, Net	20,700,000	'	20,700,000	'	23,700,000
Acquired IPR&D product rights	'	'	'	'	'
Intangible Assets By Category	'	'	'	'	'
Accumulated Amortization	0	'	0	'	0
Non-amortized intangible assets:	'	'	'	'	'
Carrying Value	1,628,700,000	'	1,628,700,000	'	137,900,000
Minimum	'	'	'	'	'
Total intangible assets	'	'	'	'	'
Amortization	'	'	255,000,000	'	'
Maximum	'	'	'	'	'
Total intangible assets	'	'	'	'	'
Amortization	'	'	265,000,000	'	'
Net change in fair value \| Licenses	'	'	'	'	'
Total intangible assets	'	'	'	'	'
Contingent consideration as liability, fair value disclosure	$58,000,000	'	$58,000,000	'	'

Debt_Details

Debt (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014	Dec. 31, 2013
Carrying values of the entity's senior notes	'	'
Long-term debt	$6,737.30	$4,196.50
2.450% senior notes due 2015	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	508.2	513.9
Interest rate (as a percent)	2.45%	'
1.900% senior notes due 2017	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	500.3	499.9
Interest rate (as a percent)	1.90%	'
2.300% senior notes due 2018	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	400.1	399
Interest rate (as a percent)	2.30%	'
2.250% senior notes due 2019	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	498.8	0
Interest rate (as a percent)	2.25%	'
3.950% senior notes due 2020	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	495.4	484.6
Interest rate (as a percent)	3.95%	'
3.250% senior notes due 2022	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	991.1	956.6
Interest rate (as a percent)	3.25%	'
4.000% senior notes due 2023	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	704	696.3
Interest rate (as a percent)	4.00%	'
3.625% senior notes due 2024	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	996.7	0
Interest rate (as a percent)	3.63%	'
5.700% senior notes due 2040	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	249.6	249.6
Interest rate (as a percent)	5.70%	'
5.250% senior notes due 2043	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	396.6	396.6
Interest rate (as a percent)	5.25%	'
4.625% senior notes due 2044	'	'
Carrying values of the entity's senior notes	'	'
Long-term debt	$996.50	$0
Interest rate (as a percent)	4.63%	'

Debt_Details_2

Debt (Details 2) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2011

Sep. 30, 2014

Dec. 31, 2013

Treasury rate lock agreements

Interest rate swap contracts

Level 2

Senior notes

2.250% senior notes due 2019

3.625% senior notes due 2024

4.625% senior notes due 2044

Commercial Paper

Senior Unsecured Credit Facility

Designated as hedging instruments

Time_Per_Annum

Debt

Senior notes, fair value

$6,866,000,000

Principal amount

2,500,000,000

500,000,000

1,000,000,000

Interest rate (as a percent)

2.25%

3.63%

4.63%

Issuance price of par value (as a percentage)

99.75%

99.66%

99.65%

Unamortized debt issuance expense

21,200,000

Redemption price (as a percentage)

101.00%

1.10%

1.15%

1.20%

Losses recorded to AOCI

53,300,000

Gains recorded as reduction of debt

32,700,000

32,100,000

Gain on settlement of contract

8,800,000

Amount outstanding

100,000,000

544,800,000

Effective interest rate (as a percent)

0.30%

Maximum borrowing capacity

1,500,000,000

Maximum number of credit facility increases

Maximum borrowing capacity, subject to certain conditions

1,750,000,000

Outstanding uncommitted facility

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	3 Months Ended		9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Stock-Based Compensation	'	'	'	'
Total share-based compensation expense	$111.40	$92	$319.20	$227.40
Tax benefit related to share-based compensation expense	31.4	29.9	92.4	66.1
Reduction in income	80	62.1	226.8	161.3
Cost of goods sold (excluding amortization of acquired intangible assets)	'	'	'	'
Stock-Based Compensation	'	'	'	'
Total share-based compensation expense	6.8	6.1	18.8	12.6
Research and development	'	'	'	'
Stock-Based Compensation	'	'	'	'
Total share-based compensation expense	48.4	41.7	141.2	100.5
Selling, general and administrative	'	'	'	'
Stock-Based Compensation	'	'	'	'
Total share-based compensation expense	$56.20	$44.20	$159.20	$114.30

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 2) (USD $)	9 Months Ended			0 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2014	Sep. 30, 2014	Sep. 30, 2014	Jun. 18, 2014	Jun. 18, 2014
	Stock Options	Restricted Stock Units	Performance- Based Restricted Stock Units (in thousands)	Common Stock	Common Stock
Share-Based Compensation	'	'	'	'	'
Aggregate share reserve (in shares)	'	'	'	'	228,000,000
New pre-split shares authorized	'	'	'	18,000,000	'
Stock option activity	'	'	'	'	'
Outstanding at the beginning of the Period (in shares)	79,200,000	'	'	'	'
Granted (in shares)	10,600,000	'	'	'	'
Exercised/Released (in shares)	-9,600,000	'	'	'	'
Forfeited (in shares)	-1,300,000	'	'	'	'
Outstanding at the end of the period (in shares)	78,900,000	'	'	'	'
Restricted and Performance-Based Restricted Stock Units	'	'	'	'	'
Nonvested at the beginning of the period, share equivalent	'	10,200,000	115,000	'	'
Granted, share equivalent	'	1,800,000	48,000	'	'
Exercised, share equivalent	'	-2,200,000	-24,000	'	'
Forfeited, share equivalent	'	-300,000	-6,000	'	'
Nonvested at the end of the period, share equivalent	'	9,500,000	133,000	'	'
Compensation cost and expected weighted-average period related to nonvested awards	'	'	'	'	'
Unrecognized compensation cost	$500.30	$277.80	$6.30	'	'
Expected weighted-average period in years of compensation cost to be recognized	'2 years 1 month 6 days	'1 year 3 months 18 days	'1 year 9 months 18 days	'	'

Income_Taxes_Details

Income Taxes (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 30, 2014
Income Tax Disclosure [Abstract]	'
Gross unrecognized tax benefits, increase	$29.20
Increases to the amount of unrecognized tax benefits	31.9
Accrued interest on unrecognized tax benefits	5
Unrecognized tax benefits, settlements from prior years	$7.70

Collaboration_Agreements_Detai

Collaboration Agreements (Details) (USD $)

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2013

Sep. 30, 2014

Mar. 21, 2014

Sep. 30, 2014

Sep. 30, 2013

Mar. 21, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Dec. 31, 2012

Sep. 30, 2014

Sutro

Agios

License payments FORMA

FORMA

NantBioScience

Other Collaboration Arrangements

Antibody drug conjugate (ADC)

Bispecific antibody construct (BAC)

Research and manufacturing

Research and development payments

Regulatory approval

research_targets

Amino_Acid_Target

Maximum

product_candidate

Sutro

FORMA

Sutro

FORMA

Collaborative_Arrangement

data_package

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

$95

$35

$72.60

[1],[2],[3]

$72.60

[1],[2],[3]

[1],[2]

$225

[1],[2]

$23.80

[1],[2]

$50

[1],[2]

$27

[1],[2]

$54

[1],[2]

$106

[1],[2]

Potential milestones payment

120

430

52.5

204

279

200

275

315

Number of prioritized anti-cancer bispecific antibody construct and antibody drug conjugates

Collaboration agreement, performance evaluation

Research and development period

'3 years

'4 years

Research and development period, extension

'1 year 6 months

Collaboration agreement, termination of agreement, period

'120 days

Collaboration agreement term

'3 years 6 months

Number of additional agreement

Term of additional agreement

'2 years

Payment to exercise additional agreements

375

Aggregate collaboration agreement payments

Number of product candidates from pipeline

Ownership percentage

15.00%

14.00%

Potential future investment

Effective notice period required to be served for termination of agreement

'30 days

Number of product candidates

Number of data packages for product candidates

Expiration period

'10 years

Percentage of outstanding equity

15.00%

[2],[3]

15.00%

[2],[3]

15.00%

[2],[3]

6.00%

[2],[3]

14.00%

[2]

14.00%

[2]

15.00%

[2]

14.00%

[2]

Selling, general and administrative

497.6

448.7

1,483.50

1,235.80

[1],[2],[3]

[1],[2]

Equity investments made during period

$11.90

[1],[2],[3]

$11.90

[1],[2],[3]

[1],[2]

$12.80

[1],[2]

$13

[1],[2]

$12.80

[1],[2]

$90

[1],[2]

$27

[1],[2]

$47.90

[1],[2]

$8.90

[1],[2]

[1]

In addition to the expenses noted in the tables above, we may also incur expenses for collaboration agreement related activities that are managed or funded by us.

[2]

Activity and balances are presented specifically for notable new collaborations and for those collaborations which we have described in detail in our 2013 Annual Report on FormÂ 10-K if there has been new activity during the periods presented. Amounts related to collaborations that are not specifically described are presented in the aggregate as Other Collaboration Arrangements.

[3]

Based on our assessment of the fair value of the components of the September 2014 agreement with Sutro, our payments of $95.0 million were allocated as $72.6 million of upfront collaboration expense, $11.9 million of equity investment asset, $9.0 million of manufacturing rights asset and $1.5 million of option to acquire asset.

Collaboration_Agreements_Perio

Collaboration Agreements (Period Activity) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

3 Months Ended

9 Months Ended

1 Months Ended

0 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Millions, unless otherwise specified

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Dec. 31, 2012

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Mar. 21, 2014

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Acceleron

Acetylon

Agios

bluebird

Epizyme

Sutro

FORMA

Morphosys

NantBioScience

Other Collaboration Arrangements

Upfront collaboration expense

Equity investment asset

Manufacturing rights asset

Option to aquire asset

Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]

Upfront Fees

[1],[2],[3]

[1],[2]

[1],[2],[4]

[1],[2],[3]

$50

[1],[2]

[1],[2],[3]

$50

[1],[2]

$74.70

[1],[2]

$94.30

[1],[2]

$95

$35

$72.60

[1],[2],[3]

$72.60

[1],[2],[3]

$72.60

$11.90

$1.50

$225

[1],[2]

$23.80

[1],[2]

$94.30

[1],[2]

$50

[1],[2]

$27

[1],[2]

$54

[1],[2]

$106

[1],[2]

Milestones

[1],[2],[3]

[1],[2]

[1],[2],[4]

[1],[2],[3]

[1],[2]

[1],[2],[3]

[1],[2]

[1],[2],[3]

[1],[2]

6.8

[1],[2]

7.3

[1],[2]

Amortization of Prepaid R&D and Intangibles

[1],[2],[3]

[1],[2]

[1],[2],[4]

4.3

[1],[2],[3]

0.6

[1],[2]

11.4

[1],[2],[3]

0.6

[1],[2]

0.1

[1],[2]

0.1

[1],[2]

0.1

[1],[2],[3]

0.5

[1],[2],[3]

0.2

[1],[2],[3]

1.6

[1],[2],[3]

0.1

[1],[2]

0.4

[1],[2]

0.8

[1],[2]

6.9

[1],[2]

1.7

[1],[2]

Selling, General and Administrative Expense

497.6

448.7

1,483.50

1,235.80

[1],[2],[3]

[1],[2]

[1],[2],[4]

[1],[2],[3]

[1],[2]

[1],[2],[3]

[1],[2]

[1],[2],[3]

[1],[2]

Equity Investments Made During Period

[1],[2],[3]

[1],[2]

52.4

[1],[2],[4]

[1],[2],[3]

[1],[2]

[1],[2],[3]

[1],[2]

12.8

[1],[2]

12.8

[1],[2]

61.3

[1],[2]

9.9

[1],[2]

11.9

[1],[2],[3]

11.9

[1],[2],[3]

[1],[2]

61.3

[1],[2]

47.9

[1],[2]

8.9

[1],[2]

Premium paid on equity investment

$9.70

[1]

In addition to the expenses noted in the tables above, we may also incur expenses for collaboration agreement related activities that are managed or funded by us.

[2]

[3]

[4]

Our additional equity investment in Acceleron made in the second quarter of 2014 was transacted at a price per share that exceeded the market value of Acceleron publicly traded common stock on the transaction closing date, resulting in an expense for the premium of $9.7 million that was recorded in the Consolidated Statements of Income as other income (expense), net in the second quarter of 2014.

Collaboration_Agreements_Perio1

Collaboration Agreements (Period End Balances) (Details) (USD $)	Sep. 30, 2014		Dec. 31, 2013
In Millions, unless otherwise specified	Sep. 30, 2014		Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	$4,131.90		$2,839.70
Acceleron	'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	0	[1]	0	[1]
Equity Investment Balance	139.5	[1]	127.2	[1]
Percentage of Outstanding Equity	14.00%	[1]	11.00%	[1]
Acetylon	'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	24.3	[1]	35.7	[1]
Equity Investment Balance	25	[1]	25	[1]
Percentage of Outstanding Equity	10.00%	[1]	10.00%	[1]
Agios	'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	0	[1]	0	[1]
Equity Investment Balance	307.6	[1]	113	[1]
Percentage of Outstanding Equity	14.00%	[1]	15.00%	[1]
bluebird	'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	0.1	[1]	0.2	[1]
Equity Investment Balance	0	[1]	0	[1]
Epizyme	'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	0	[1]	0	[1]
Equity Investment Balance	99.6	[1]	69.4	[1]
Percentage of Outstanding Equity	11.00%	[1]	12.00%	[1]
Sutro	'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	12.8	[1],[2]	2.5	[1],[2]
Equity Investment Balance	17.6	[1],[2]	5.7	[1],[2]
Percentage of Outstanding Equity	15.00%	[1],[2]	6.00%	[1],[2]
FORMA	'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	0.1	[1]	0.2	[1]
Equity Investment Balance	0	[1]	0	[1]
Morphosys	'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	0	[1]	0	[1]
Equity Investment Balance	78.2	[1]	61.4	[1]
Percentage of Outstanding Equity	3.00%	[1]	3.00%	[1]
NantBioScience	'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	0	[1]	'
Equity Investment Balance	90	[1]	'
Percentage of Outstanding Equity	14.00%	[1]	'
Other Collaboration Arrangements	'		'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'		'
Intangible Asset Balance	32	[1]	23.1	[1]
Equity Investment Balance	$78.30	[1]	$49.50	[1]

[1]	Activity and balances are presented specifically for notable new collaborations and for those collaborations which we have described in detail in our 2013 Annual Report on FormÂ 10-K if there has been new activity during the periods presented. Amounts related to collaborations that are not specifically described are presented in the aggregate as Other Collaboration Arrangements.
[2]	Based on our assessment of the fair value of the components of the September 2014 agreement with Sutro, our payments of $95.0 million were allocated as $72.6 million of upfront collaboration expense, $11.9 million of equity investment asset, $9.0 million of manufacturing rights asset and $1.5 million of option to acquire asset.

Legal_Proceedings_Details

Legal Proceedings (Details) (USD $)	0 Months Ended	1 Months Ended		0 Months Ended
	Apr. 11, 2014	Feb. 28, 2014	Dec. 31, 2013	Jun. 07, 2013	Jun. 07, 2013
	Andrulis Pharmaceuticals Corporation Patent Infringement	Litigation Related to Sales of THALOMID and REVLIMID	Children's Medical Center Corporation	Children's Medical Center Corporation	Children's Medical Center Corporation
	lawsuit	plaintiff		revlimid royalty	pomalyst royalty
		lawsuit
Loss Contingencies [Line Items]	'	'	'	'	'
Claims dismissed	2	'	'	'	'
Patents allegedly infringed	4	'	'	'	'
Number of civil qui tam actions	'	3	'	'	'
Number of plaintiffs	'	3	'	'	'
Royalty rate	'	'	'	0.01	0.025
Range of possible loss, minimum	'	'	$0	'	'
Range of possible loss, maximum	'	'	$72,400,000	'	'